0001554795-18-000243.txt : 20180817 0001554795-18-000243.hdr.sgml : 20180817 20180817152559 ACCESSION NUMBER: 0001554795-18-000243 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180817 DATE AS OF CHANGE: 20180817 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALTAIR INTERNATIONAL CORP. CENTRAL INDEX KEY: 0001570937 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 990385465 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-190235 FILM NUMBER: 181025670 BUSINESS ADDRESS: STREET 1: 2360 CORPORATE CIRCLE STE 400 CITY: HENDERSON STATE: NV ZIP: 89074-7722 BUSINESS PHONE: 702-988-8801 MAIL ADDRESS: STREET 1: 2360 CORPORATE CIRCLE STE 400 CITY: HENDERSON STATE: NV ZIP: 89074-7722 10-K 1 atao0814form10k.htm FORM 10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED MARCH 31, 2018

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

COMMISSION FILE NO. 333-190235

ALTAIR INTERNATIONAL CORP.

(Exact name of registrant as specified in its charter)

Nevada

(State or Other Jurisdiction of Incorporation or Organization)

99-0385465

IRS Employer Identification Number

Altair International Corp.

6501 E. Greenway Pkwy #103-412

Scottsdale, AZ 85254

Tel. (760) 413-3927

(Address and telephone number of principal executive offices)

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: None

1 | Page

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☑

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☑

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant as required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☑

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (X 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☑

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☐ (Do not check if a smaller reporting company)	Smaller reporting company ☑
	Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) Yes ☑No ☐

As of August 13, 2018, the registrant had 74,509,883 shares of common stock issued and outstanding. No market value has been computed based upon the fact that no active trading market has been established as of August 17, 2018.

2 | Page

TABLE OF CONTENTS


	PART 1
ITEM 1	Description of Business	4
ITEM 1A	Risk Factors	5
ITEM 2	Description of Property	5
ITEM 3	Legal Proceedings	5
ITEM 4	Mine Safety Disclosures	5
	PART II
ITEM 5	Market for Common Equity and Related Stockholder Matters	6
ITEM 6	Selected Financial Data	6
ITEM 7	Management's Discussion and Analysis of Financial Condition and Results of Operations	6
ITEM 7A	Quantitative and Qualitative Disclosures about Market Risk	8
ITEM 8	Financial Statements and Supplementary Data	9
ITEM 9	Changes In and Disagreements with Accountants on Accounting and Financial Disclosure	17
ITEM 9A (T)	Controls and Procedures	17
	PART III
ITEM 10	Directors, Executive Officers, Promoters and Control Persons of the Company	17
ITEM 11	Executive Compensation	18
ITEM 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	19
ITEM 13	Certain Relationships and Related Transactions	19
ITEM 14	Principal Accountant Fees and Services	19
	PART IV
ITEM 15	Exhibits	20

3 | Page

FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections. We may use words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “foresee,” “estimate” and variations of these words and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted. These risks and uncertainties include the following:

The availability and adequacy of working capital to meet our requirements;

Actions taken or omitted to be taken by legislative, regulatory, judicial and other governmental authorities;

Changes in our business strategy or development plans;

The availability of additional capital to support capital improvements and development;

Other risks identified in this report and in our other filings with the Securities and Exchange Commission or the SEC; and

The availability of new business opportunities.

This report should be read completely and with the understanding that actual future results may be materially different from what we expect. The forward looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this Report. We will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Term

Except as otherwise indicated by the context hereof, references in this report to “Company,” “ATAO,” “we,” “us” and “our” are references to Altair International Corp. All references to “USD” or United States Dollars refer to the legal currency of the United States of America.

PART I

ITEM 1. DESCRIPTION OF BUSINESS

Our Business

The Company is currently engaged in identifying and assessing new business opportunities.

On November 11, 2014, the Company entered into a strategic alliance with Cure Pharmaceutical Corporation (“CURE”), a California company engaged in the development of oral thin film (“OTF”) for the delivery of nutraceutical, over-the-counter and prescription products. Initially this alliance was comprised of an Exclusive License and Distribution Agreement for CURE’s Sildenafil (commonly known as Viagra) Products throughout Asia, Brazil, the Middle East and Canada acquired at a cost of $200,000 while a joint venture agreement for the procurement of converting and packaging equipment specific for oral thin film products was proposed through a Letter of Intent. In addition, Altair and Cure agreed to enter into further joint ventures or other business relationships for the purpose of completing the development and marketing of additional products, and for license and distribution agreements for additional Cure products such as aspirin, sleep-aid, topical muscle and joint pain relief, and electrolytes delivered through OTF or other methods. Altair advanced $360,000 to CURE in this regard.

On September 23, 2016, the Company and CURE agreed to terminate the Exclusive License and Distribution Agreement for CURE’s Sildenafil Products due to unanticipated costs of obtaining regulatory approvals for the introduction of these pharmaceutical products into the licensed markets. The Company and CURE agreed to replace it with an Exclusive License and Distribution Agreement for a family of sports related nutraceutical products including a topical active for joint and muscle pain and OTF products for delivery of electrolyte, energy, sleep and recovery actives. The Company was to become the exclusive worldwide distributor for these products. The fee for this new sport products agreement was $560,000, comprised of the $200,000 fee paid for the Sildenafil agreement and the $360,000 advanced as a deposit for future license and distribution agreements. The agreement called for minimum orders of the products by Altair of $1,500,000 in the twenty-four months from the date of signing. As of June 29, 2018, the Company has been unable to generate any sales of the products due to a lack of working capital and the human resources required to introduce the products to market. The Company anticipates that it will not meet the minimum order requirements for the initial 24 month period and accordingly wrote off its $560,000 investment in the agreement in these financial statements for the year ended March 31, 2017.

The Company had previously planned to commence operations in the architectural field and to be responsible for the concept architectural vision of future private and public buildings as well as municipal organized public areas. This plan was abandoned in the 2015 fiscal year in favor of the business operations described above.

Property Acquisitions

None

Intellectual Property

The Company does not own any intellectual property and has yet to incur any expenses for research and development other than as disclosed herein.

Employees

As of the date of this Report, the Company has no full-time nor part-time employees. Our sole officer and director does not have a current agreement with the Company to serve in these capacities. We intend to increase the number of our employees and consultants to meet our needs as the Company grows.

WHERE YOU CAN GET ADDITIONAL INFORMATION

We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy our reports or other filings made with the SEC at the SEC’s Public Reference Room, located at 100 F Street, N.W., Washington, DC 20549. You can obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. You can also access these reports and other filings electronically on the SEC’s web site, www.sec.gov.

4 | Page

ITEM 1A. RISK FACTORS

Not applicable to smaller reporting companies.

ITEM 2. DESCRIPTION OF PROPERTY

We do not own any real estate or other properties.

ITEM 3. LEGAL PROCEEDINGS

We are not currently involved in any legal proceedings and we are not aware of any pending or potential legal actions.

ITEM 4. MINE SAFETY DISCLOSURES

None.

5 | Page

PART II

ITEM 5. MARKET FOR COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

There is a limited public market for our common shares. Our common shares are quoted on the OTC Market under the symbol “ATAO” although there has been no active trading market in our shares since inception. Trading in stocks quoted on the OTC Market is often thin and is characterized by wide fluctuations in trading prices due to many factors that may be unrelated to a company’s operations or business prospects. We cannot assure you that there will be a market in the future for our common stock.

OTC Market securities are not listed or traded on the floor of an organized national or regional stock exchange. Instead, OTC Market securities transactions are conducted through a telephone and computer network connecting dealers in stocks. OTC Market issuers are traditionally smaller companies that do not meet the financial and other listing requirements of a regional or national stock exchange.

Number of Holders

As of August 13, 2018, 74,509,883 issued and outstanding shares of common stock were held by 72 shareholders of record.

Dividends

No cash dividends were paid on our shares of common stock during the fiscal year ended March 31, 2018. We have not paid any cash dividends since our inception and do not foresee declaring any cash dividends on our common stock in the foreseeable future.

Recent Sales of Unregistered Securities

None.

Purchase of our Equity Securities by Officers and Directors

None.

Other Stockholder Matters

None.

ITEM 6. SELECTED FINANCIAL DATA

Not applicable.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward looking statements. Our audited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

6 | Page

RESULTS OF OPERATIONS

We have incurred recurring losses to date. Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.

We expect we will require additional capital to meet our long term operating requirements. We expect to raise additional funds through, among other things, the sale of equity or debt securities although no assurance can be given as to availability of funds or the terms thereof.

FISCAL YEAR ENDED MARCH 31, 2018 COMPARED TO FISCAL YEAR ENDED MARCH 31, 2017

Our net gain for the fiscal year ended March 31, 2018 was $167,319 compared to a net loss of $736,774 for the fiscal year ended March 31, 2017. During fiscal years ended March 31, 2018 and March 31, 2017, the Company did not generate any revenue.

During the fiscal year ended March 31, 2018, we incurred general and administrative expenses of $3,807 compared to $80,253 in general and administrative expenses incurred during the fiscal year ended March 31, 2017.

Expenses incurred during fiscal year ended March 31, 2018 compared to the fiscal year ended March 31, 2017 decreased primarily due to the decreased scale and scope of business operations. General and administrative expenses generally include corporate overhead and financial and administrative contracted services.

The weighted average number of shares outstanding was 39,441,144 for the fiscal year ended March 31, 2018 and 30,902,589 for the fiscal year ended March 31, 2017.

LIQUIDITY AND CAPITAL RESOURCES

FISCAL YEAR ENDED MARCH 31, 2018

As of March 31, 2018, our current assets were $75 and our total liabilities were $78,467. As of March 31, 2018, current assets were comprised of $75 in cash. As of March 31, 2018, total liabilities were comprised of accounts payable of $17,948, interest payable of $1,354, loans payable to third parties of $14,165 and a promissory note due to a related party in the amount of $45,000. As of March 31, 2018, our total assets were comprised of $75 in cash. Stockholders’ deficit was $78,392 as of March 31, 2018.

As of March 31, 2017, our current assets were $7,523 and our total liabilities were $648,763. As of March 31, 2017, current assets were comprised of $7,523 in cash. As of March 31, 2017, total liabilities were comprised of interest payable of $12,575, promissory notes for $292,299, a derivative liability of $308,134, loans payable to third parties of $14,165 and $21,590 in accounts payable. As of March 31, 2017, our total assets were comprised of $7,523 in cash. Stockholders’ deficit was $641,240 as of March 31, 2017.

Cash Flows from Operating Activities

We did not generate positive cash flows from operating activities in the year ended March 31, 2018. For the fiscal year ended March 31, 2018 net cash flows used in operating activities were $7,448 consisting of a net gain of $167,319, decreases of $3,642 in accounts payable and $244,717 in the fair value of derivative liabilities, increases of $12,722 in interest payable and $124,287 in debt discount and a $63,417 gain on conversion of debt.

For the fiscal year ended March 31, 2017 net cash flows used in operating activities were $58,983 consisting of a net loss of $736,774, the write off of sales and distribution licenses in the amount of $560,000, increases of $21,270 in accounts payable, $12,674 in interest payable and $125,364 in debt discount, and decreases of $41,517 in the fair value of derivative liabilities.

Cash Flows from Financing Activities

We have financed our operations primarily from either advances from shareholders or the issuance of equity and debt instruments. For the year ended March 31, 2018 no cash was provided from financing activities.

For the year ended March 31, 2017 cash was provided from financing activities including net repayments of loans from third parties of $12,510, proceeds of $43,594 from the issuance of promissory notes and proceeds of common stock issuances of $30,000.

7 | Page

PLAN OF OPERATION AND FUNDING

We expect that working capital requirements will continue to be funded through a combination of our existing funds, advances from shareholders and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business.

Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next six months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business); (ii) acquisition of assets; and (iii) sales and marketing expenses. We intend to finance these expenses with further issuances of securities and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

MATERIAL COMMITMENTS

As of the date of this Annual Report, we do not have any material commitments.

PURCHASE OF SIGNIFICANT EQUIPMENT

As of the date of this Annual Report, we do not anticipate the purchase of any significant equipment.

OFF-BALANCE SHEET ARRANGEMENTS

As of the date of this Annual Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

GOING CONCERN

The independent auditors' report accompanying our March 31, 2018 and March 31, 2017 financial statements contains an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. The financial statements have been prepared "assuming that we will continue as a going concern," which contemplates that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to smaller reporting companies.

8 | Page

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Report of Independent Registered Public Accounting Firm		F–1

Balance Sheets		F–2

Statements of Operations		F–3

Statement of Stockholders’ Equity		F–4

Statements of Cash Flows		F–5

Notes to the Financial Statements		F–6

9 | Page

MICHAEL GILLESPIE & ASSOCIATES, PLLC

CERTIFIED PUBLIC ACCOUNTANTS

10544 ALTON AVE NE

SEATTLE, WA 98125

206.353.5736

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors

Altair International Corp.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Altair International Corp. as of March 31, 2018 and 2017 and the related statements of operations, changes in stockholder’s deficit, cash flows, and the related notes (collectively referred to as “financial statements”) for the periods then ended. In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2018 and 2017 and the results of its operations and its cash flows for the periods then ended, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note #2 to the financial statements, although the Company has limited operations it has yet to attain profitability. This raises substantial doubt about its ability to continue as a going concern. Management’s plan in regard to these matters is also described in Note #2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/S/ MICHAEL GILLESPIE & ASSOCIATES, PLLC

We have served as the Company’s auditor since 2017.

Seattle, Washington

August 6, 2018

F-1

ALTAIR INTERNATIONAL CORP.
BALANCE SHEETS
AUDITED

		March 31, 2018			March 31, 2017
ASSETS
Current Assets
Cash	$	75		$	7,523
Total current assets		75			7,523

Total assets	$	75		$	7,523

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable	$	17,948		$	21,590
Loans payable		14,165			14,165
Interest payable		1,354			12,575
Promissory notes due to third parties		—			241,217
Promissory note due to related party		45,000			51,082
Derivative liability		—			308,134
Total current liabilities		78,467			648,763
Total Liabilities		78,467			648,763

Stockholders' Equity (Deficit)
Common Stock, $0.001 par value, 75,000,000 shares authorized; 47,747,245 shares issued and outstanding at March 31, 2018 (31,957,000 at March 31, 2017)		47,747			31,957
Additional paid-in-capital		432,052			289,940
Common Stock subscribed		267,627			30,000
Accumulated deficit		(825,818	)		(993,137	)
Total stockholders' equity (deficit)		(78,392	)		(641,240	)
Total liabilities and stockholders's equity (deficit)	$	75		$	7,523


The accompanying notes are an integral part of these financial statements

F-2

ALTAIR INTERNATIONAL CORP.
STATEMENTS OF OPERATIONS
AUDITED

	Year ended March 31, 2018			Year ended March 31, 2017
Expenses
Total General and Administrative expenses	$	3,807		$	80,253
Write off of Sales and Distribution Licenses		—			560,000
Gain on conversion of debt		(63,417	)		—
Derivative expense		(244,717	)		(41,517	)
Interest expense		137,008			138,038

Loss (gain) before income taxes		(167,319	)		736,774
Income taxes		—			—
Net loss (gain)	$	(167,319	)	$	736,774

Loss (gain) per share - Basic	$	0.004		$	(0.024	)
Weighted Average Shares - Basic		39,441,144			30,902,589


The accompanying notes are an integral part of these financial statements.

F-3

ALTAIR INTERNATIONAL CORP.
STATEMENTS OF STOCKHOLDERS' DEFICIT
AUDITED

	Number of Common Shares		Amount		Additional Paid-In-Capital		Capital Stock Subscribed		Accumulated Deficit			Total
Balance at March 31, 2015		29,645,000	$	29,645	$	7,146		—	$	(102,536	)		(65,745	)
Common shares issued for cash		302,000		302		264,704		—		—			265,006
Net loss for the period ended March 31, 2016 (Restated)		—		—		—		—		(153,827	)		(153,827	)
Balance at March 31, 2016 (Restated)		29,947,000	$	29,947	$	271,850		—	$	(256,363	)		45,434
Common shares issued on conversion of Promissory Notes		2,000,000		2,000		18,000		—		—			20,000
Common shares issued for debt		10,000		10		90		—		—			100
Common stock subscribed		—		—		—		30,000		—			30,000
Net loss for the year ended March 31, 2017		—		—		—		—		(736,774	)		(736,774	)
Balance at March 31, 2017		31,957,000	$	31,957	$	289,940		30,000	$	(993,137	)		(641,240	)
Common shares issued on conversion of Promissory Notes		15,790,245		15,790		142,112							157,902
Common Stock subscribed		—		—		—		237,627					237,627
Net income for the year ended March 31, 2018		—		—		—		—		167,319			167,319
Balance at March 31, 2018		47,747,245	$	47,747	$	432,052	$	267,627	$	(825,818	)		(78,392	)


The accompanying notes are an integral part of these financial statements.

F-4

ALTAIR INTERNATIONAL CORP.
STATEMENTS OF CASH FLOWS
AUDITED

		Year ended March 31, 2018			Year ended March 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net gain (loss)	$	167,319		$	(736,774	)
Adjustments to reconcile net loss to net cash used in operating activities
Changes in:
Accounts payable		(3,642	)		21,270
Interest payable		12,722			12,674
Fair value of derivative liabilities		(244,717	)		(41,517	)
Gain on conversion of debt		(63,417	)
Debt discount		124,287			125,364
Write off of sales and distribution licenses					560,000
		(7,448	)		(58,983	)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from Promissory Note					43,594
Proceeds from Loans					(12,510	)
Proceeds from common stock subscriptions					30,000
		—			61,084

NET INCREASE IN CASH AND CASH EQUIVALENTS		(7,448	)		2,101

CASH AND CASH EQUIVALENTS
Beginning of year		7,523			5,422
End of year	$	75			7,523

Supplemental disclosures of cash flow information
Taxes paid	$	—			—
Interest paid	$	—			—

Non-Cash Financing and Investing Activities
Capital Stock subscribed for
Conversion of loans from third parties	$	30,000		$	—
Conversion of Promissory Notes to third parties		332,213			—
Conversion of Promissory Note to related party		39,373			—
Accrued Interest on Promissory Notes		23,943			—
		425,529			—

Promissory Notes issued in settlement of loans	$	—		$	436,586
Debt discount on issuance of Promissory Notes					(249,651	)
	$	—		$	186,935

Interest expense - debt discount in period	$	124,287		$	—

Derivative Liability on issuance of Promissory Notes	$	—		$	349,651

Reduction of derivative liability in period	$	252,896		$	4,227
Reduction of derivative liability - mark to market on
conversion of Promissory Notes		55,239			—
	$	308,135		$	4,227


The accompanying notes are an integral part of these financial statements.

F-5

ALTAIR INTERNATIONAL CORP.

NOTES TO THE FINANCIAL STATEMENTS

MARCH 31, 2018 and MARCH 31, 2017

AUDITED

NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS

Organization and Description of Business

ALTAIR INTERNATIONAL CORP. (the “Company”) was incorporated under the laws of the State of Nevada on December 20, 2012. The Company’s physical address is 18934 N 92^nd Way, Scottsdale, AZ 85255. The Company is in the development stage as defined under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915-205 "Development-Stage Entities.”

On September 23, 2016, the Company and CURE agreed to terminate the Exclusive License and Distribution Agreement for CURE’s Sildenafil Products due to unanticipated costs of obtaining regulatory approvals for the introduction of these pharmaceutical products into the licensed markets. In its place, the Company and CURE agreed to replace it with an Exclusive License and Distribution Agreement for a family of sports related nutraceutical products including a topical active for joint and muscle pain and OTF products for delivery of electrolyte, energy, sleep and recovery actives. The Company was to become the exclusive worldwide distributor for these products. The fee for this new sport products agreement was $560,000, comprised of the $200,000 fee paid for the Sildenafil agreement and the $360,000 advanced as a deposit for future license and distribution agreements. The agreement called for minimum orders of the products by Altair of $1,500,000 in the twenty-four months from the date of signing. As of June 29, 2018, the Company has been unable to generate any sales of the products due to a lack of working capital and the human resources required to introduce the products to market. The Company anticipates that it will not meet the minimum order requirements for the initial 24 month period and accordingly wrote off its $560,000 investment in the agreement in these financial statements for the year ended March 31, 2017.

The Company is currently engaged in identifying and assessing new business opportunities.

Since inception (December 20, 2012) through March 31, 2018, the Company has not generated any revenue and has accumulated losses of $825,818.

In management’s opinion all adjustments necessary for a fair statement of the results for the interim periods have been made, and that all adjustments have been made to maintain the books in accordance with GAAP. Furthermore, sufficient disclosures have been made in order to ensure that the interim financial statements will not be misleading.

NOTE 2 - GOING CONCERN

These financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception resulting in an accumulated deficit of $825,818 as of March 31, 2018 and further losses are anticipated in the development of its business raising substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and/or private placement of common stock.

F-6

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the years ending March 31, 2018 and 2017.

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.

The Company's bank accounts are deposited in insured institutions. The funds are insured up to $250,000. At March 31, 2018 the Company's bank deposits did not exceed the insured amounts.

Basic and Diluted Income (Loss) Per Share

The Company computes loss per share in accordance with “ASC-260”, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive.

Income Taxes

The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Fair Value of Financial Instruments

FASB ASC 820 "Fair Value Measurements and Disclosures" establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

These tiers include:

Level 1: defined as observable inputs such as quoted prices in active markets;

Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The carrying amounts of financial assets and liabilities, such as cash and accrued liabilities approximate their fair values because of the short maturity of these instruments.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Reclassifications

Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the financial statements for the year ended March 31, 2018.

F-7

NOTE 4 – SALES AND DISTRIBUTION LICENSE

On November 26, 2014, the Company entered into a license and distribution agreement with Cure Pharmaceutical Corporation (“Cure”) for the exclusive rights to distribute and sell in certain defined territories any product produced and supplied by Cure that contains Sildenafil delivered through an oral thin film. The defined territories included Asia, Brazil, the Middle East and Canada. For the sake of clarity, Asia was further defined as India, China, Malaysia, Indonesia, Taiwan, Japan, Philippines, and those other countries dependent on China’s SDA certification for their approval protocol of the Products. There was no expiry date to this agreement. The agreement required that the Company pay to Cure a fee in the aggregate amount of $200,000, payable in two equal $100,000 instalments. The Company completed the purchase of the license in the 2015 fiscal year.

On September 23, 2016, the Company and CURE agreed to terminate the Exclusive License and Distribution Agreement for CURE’s Sildenafil Products due to unanticipated costs of obtaining regulatory approvals for the introduction of these pharmaceutical products into the Asian markets and to replace it with an Exclusive License and Distribution Agreement for a family of sports related nutraceutical products including a topical active for joint and muscle pain and OTF products for delivery of electrolyte, energy, sleep and recovery actives, The Company became the exclusive worldwide distributor for these products. The fee for this new Exclusive License and Distribution Agreement was $560,000, comprised of the $200,000 fee paid for the Sildenafil agreement and the $360,000 advanced as a deposit for future license and distribution agreements. This Agreement has a ten year term and requires minimum product orders of $1,500,000 in the first 24 months from the effective date of the Agreement and $1,500,000 for each year thereafter. As of June 29, 2018, the Company had been unable to generate any sales of the products due to a lack of working capital and the human resources required to introduce the products to market. The Company anticipates that it will not meet the minimum order requirements for the initial 24 month period and accordingly wrote off its $560,000 investment in the agreement as at March 31, 2017 in these financial statements.

NOTE 5 – PROMISSORY NOTES

On March 6, 2015, the Company executed a convertible promissory note for $100,000 with Williams Ten, LLC (“Williams”). The note was due in ninety days, had a $10,000 one-time interest payment due at maturity and required the issuance of 10,000 shares of common stock. Any unpaid principal and interest at the end of the term was convertible into shares of common stock at 50% of the average closing price for the ten days prior to the end of the term of the note. The fair value of the common stock issued was determined to be $9,091 based on its fair value relative to the fair value of the debt issued. This amount was recorded as a debt discount and was to be amortized utilizing the interest method of accretion over the term of the note. In addition, due to the variable nature of the conversion feature which has no explicit limit on the number of shares that could be required to be issued, the company bifurcated the conversion feature and accounted for it as a derivative liability. The Company recorded the derivative liability at its fair value of $100,004 based on the Black Scholes Merton pricing model and a corresponding debt discount of $90,909 and derivative expense charge of $9,095. On September 29, 2016, Williams agreed to cancel this Promissory Note and accept a new Convertible Promissory Note in the amount of $121,000, which included all accrued interest and penalties. This Convertible Promissory Note bears interest at the rate of 6.00% per annum and has a one-year term. The Holder is entitled to convert any or all of the principal amount of this Note and any accrued interest, late fee, and extension fee, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 as is obtained by dividing the entire principal amount of this Note plus any accrued interest by $0.01 per share. On October 3, 2016, Williams converted $10,000 of the principal balance into 1,000,000 shares of common stock. On September 29, 2017, Williams converted the remaining principal of $111,000 plus $6,691 of accrued interest into 11,769,123 shares of common stock. The Company recognized a gain of $15,215 on conversion of the note and a gain on the fair value of the derivative of $16,504. As of September 30, 2017, this note had a $0 balance.

On September 23, 2016, the Company issued two Convertible Promissory Notes in the principal amounts of $10,000 and $25,000 to Enpos Sports, LLC (“Enpos”) as consideration for $35,000 in cash advances to the Company. These convertible Promissory Notes bear interest at the rate of 6.00% per annum and have a one-year term. The Holder is entitled to convert any or all of the principal amount of these Notes and any accrued interest, late fees, and extension fees, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 as is obtained by dividing the entire principal amount of the Notes plus any accrued interest at the lesser of (i) 70% of the lowest closing bid price over the 5 trading days prior to conversion or (ii) $0.10 per share. Due to the variable nature of the conversion feature which has no explicit limit on the number of shares that could be required to be issued, the company bifurcated the conversion feature and accounted for it as a derivative liability on both notes. The Company recorded the derivative liability at its fair value of $27,673 based on the Black Scholes Merton pricing model and a corresponding debt discount of $27,673 to be amortized utilizing the interest method of accretion over the term of the note. On September 29, 2017, Enpos converted the principal of $35,000 plus $2,135 of accrued interest into 3,713,452 shares of common stock. The Company recognized a gain of $4,766 on conversion of the note, a gain on the fair value of the derivative of $5,197 and amortized the remaining debt discount of $6,445 to interest expense. As of September 30, 2017, this note had a $0 balance.

F-8

On September 29, 2016, the Company issued a Convertible Promissory Note in the principal amount of $13,850 to Strips Nutrition, Inc. (“Strips”) as consideration for $13,850 in cash advances to the Company. This Convertible Promissory Note bears interest at the rate of 6.00% per annum and has a one-year term. The Holder is entitled to convert any or all of the principal amount of this Note and any accrued interest, late fee, and extension fee, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 as is obtained by dividing the entire principal amount of this Note plus any accrued interest by $0.01 per share. The company bifurcated the conversion feature and accounted for it as a derivative liability. The Company recorded the derivative liability at its fair value of $10,960 based on the Black Scholes Merton pricing model and a corresponding debt discount of $10,960 to be amortized utilizing the interest method of accretion over the term of the note. On September 29, 2017, Strips converted the principal of $13,850 plus $831 of accrued interest into 1,468,100 shares of common stock. The Company recognized a gain of $1,886 on conversion of the note, a gain on the fair value of the derivative of $2,056 and amortized the remaining debt discount of $2,733 to interest expense. As of September 30, 2017, this note had a $0 balance.

On September 29, 2016, the Company issued a Convertible Promissory Note in the principal amount of $13,768.89 to Mr. Fred Lee as consideration for $13,768.89 in travel expenses incurred in assessing distribution opportunities in Asia for the Company. This Convertible Promissory Note bears interest at the rate of 6.00% per annum and has a one-year term. The Holder is entitled to convert any or all of the principal amount of this Note and any accrued interest, late fee, and extension fee, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 (the “Common Stock”) as is obtained by dividing the entire principal amount of this Note plus any accrued interest by $0.01 per share. The company bifurcated the conversion feature and accounted for it as a derivative liability. The Company recorded the derivative liability at its fair value of $10,896 based on the Black Scholes Merton pricing model and a corresponding debt discount of $10,896 to be amortized utilizing the interest method of accretion over the term of the note. On September 29, 2017, Mr. Lee converted the principal of $13,768.89 plus $826 of accrued interest into 1,459,502 shares of common stock. The Company recognized a gain of $1,887 on conversion of the note, a gain on the fair value of the derivative of $2,047 and amortized the remaining debt discount of $2,716 to interest expense. As of September 30, 2017, this note had a $0 balance.

On September 29, 2016, the Company issued a Convertible Promissory Note in the principal amount of $160,000 to Mr. Brent McMahon as consideration for $160,000 in cash advances to the Company. This Convertible Promissory Note bears interest at the rate of 6.00% per annum and has a one-year term. The Holder is entitled to convert any or all of the principal amount of this Note and any accrued interest, late fee, and extension fee, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 (the “Common Stock”) as is obtained by dividing the entire principal amount of this Note plus any accrued interest by $0.01 per share. The company bifurcated the conversion feature and accounted for it as a derivative liability. The Company recorded the derivative liability at its fair value of $126,612 based on the Black Scholes Merton pricing model and a corresponding debt discount of $126,612 to be amortized utilizing the interest method of accretion over the term of the note. On October 3, 2016, Mr. McMahon converted $10,000 of the principal balance into 1,000,000 shares of common stock. On September 29, 2017, Mr. McMahon converted the remaining principal of $150,000 plus $7,902 of accrued interest into 15,790,245 shares of common stock. The Company recognized a gain of $20,453 on conversion of the note, a gain on the fair value of the derivative of $22,303 and amortized the remaining debt discount of $31,567 to interest expense. As of September 30, 2017, this note had a $0 balance.

On September 29, 2016, the Company issued a Convertible Promissory Note in the principal amount of $84,373.25 to Evolution Equities Corporation (“Evolution”), a related company, as consideration for $84,373.25 in expenses paid on behalf of the Company. This Convertible Promissory Note bears interest at the rate of 6.00% per annum and has a one-year term. The Holder is entitled to convert any or all of the principal amount of this Note and any accrued interest, late fee, and extension fee, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 (the “Common Stock”) as is obtained by dividing the entire principal amount of this Note plus any accrued interest by $0.01 per share. The company bifurcated the conversion feature and accounted for it as a derivative liability. The Company recorded the derivative liability at its fair value of $66,766 based on the Black Scholes Merton pricing model and a corresponding debt discount of $66,766 to be amortized utilizing the interest method of accretion over the term of the note. On September 29, 2017, Evolution converted $39,373 of principal and $5,062 accrued interest into 4,443,565 shares of common stock. A new non-convertible unsecured, 6% promissory note for the remaining principal balance of $45,000 was issued. The new note matures in eighteen months. The Company recognized a gain of $17,898 on conversion of the note, a gain on the fair value of the derivative of $5,854 and amortized the remaining debt discount of $16,645 to interest expense. As of September 30, 2017, this note had a $0 balance.

On October 14, 2016, the Company issued a Convertible Promissory Note in the principal amount of $8,594.48 to Enpos Sports, LLC (“Enpos”) as consideration for $8,594.48 in cash advances to the Company. The convertible Promissory Note bears interest at the rate of 6.00% per annum and has a one-year term. The Holder is entitled to convert any or all of the principal amount of this Note and any accrued interest, late fees, and extension fees, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 (the “Common Stock”) as is obtained by dividing the entire principal amount of the Note plus any accrued interest at the lesser of (i) 70% of the lowest closing bid price over the 5 trading days prior to conversion or (ii) $0.10 per share. Due to the variable nature of the conversion feature which has no explicit limit on the number of shares that could be required to be issued, the company bifurcated the conversion feature and accounted for it as a derivative liability. The Company recorded the derivative liability at its fair value of $6,744 based on the Black Scholes Merton pricing model and a corresponding debt discount of $6,744 to be amortized utilizing the interest method of accretion over the term of the note. On September 29, 2017, Enpos converted the principal of $8,594.48 plus $494 of accrued interest into 908,896 shares of common stock. The Company recognized a gain of $1,322 on conversion of the note, a gain on the fair value of the derivative of $1,278 and amortized the remaining debt discount of $1,940 to interest expense. As of September 30, 2017, this note had a $0 balance.

F-9

A summary of outstanding convertible notes as of March 31, 2018, is as follows:

Note Holder

Issue Date

Maturity Date

Stated Interest Rate

Principal Balance 03/31/2018

Enpos Sports, LLC

9/23/2016

9/23/2017

—

Williams Ten, LLC

9/29/2016

9/29/2017

—

Strips Nutrition, Inc.

9/29/2016

9/29/2017

—

Mr. Fred Lee

9/29/2016

9/29/2017

—

Mr. Brent McMahon

9/29/2016

9/29/2017

—

Evolution Equities Corporation

9/29/2016

9/29/2017

—

Enpos Sports, LLC

10/14/2016

10/14/2017

—

Total

—

Less debt discount

—

Total

—

A summary of the activity of the derivative liability for the notes above is as follows:

Balance at March 31, 2016	$	100,000
Increase to derivative due to new issuances		249,651
Derivative (gain) due to mark to market adjustment		(41,517	)
Balance at March 31, 2017		308,134
Derivative (gain) due to conversion		(63,417	)
Derivative (gain) due to mark to market adjustment		(244,717	)
Balance at March 31, 2018	$	—

A summary of quantitative information about significant unobservable inputs (Level 3 inputs) used in measuring the Company’s derivative liabilities that are categorized within Level 3 of the fair value hierarchy as follows:

Inputs	September 30, 2017		Initial Valuation
Stock price	$	.01	$	.01
Conversion price	$	.01	$	.01
Volatility (annual)		74.2%		248.1% - 248.6%
Risk-free rate		1.06%		.59% - .60%
Years to maturity		.25		1

The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.

NOTE 6 – LOANS PAYABLE

On July 22, 2015, the Company obtained a loan from a third party in the amount of $25,000. This loan was non-interest bearing, was unsecured and had no fixed terms of repayment. The loan was repaid in its entirety on September 29, 2016.

During the fiscal year ended March 31, 2016, the Company obtained a loan from a third party in the amount of $4,175. A further $9,990 was loaned to the Company in the 2017 fiscal year. This loan is non-interest bearing, is unsecured and has no fixed terms of repayment.

In the three month period ended March 31, 2016, the Company obtained loans from a third party in the total amount of $11,350. In the three month period ended June 30, 2016, the Company received a further $2,500 in loans from this same third party. These loans totaling $13,850 were non-interest bearing, unsecured and had no fixed terms of repayment. On September 29, 2016 these loans were settled through the issuance of a Convertible Promissory Note as described in item 5(2) above.

NOTE 7 – SHARE SUBSCRIPTIONS

On December 30, 2016, the Company received $30,000 from a third party as a subscription for 3,000,000 common shares at $0.01 per share. These shares were issued to the subscribers on April 19, 2018.

NOTE 8 – COMMON STOCK

The Company has 75,000,000 common shares authorized with a par value of $0.001 per share.

The Company had 29,947,000 common shares issued and outstanding at March 31, 2016.

During the twelve month period ended March 31, 2017 the Company issued 2,000,000 common shares on the conversion of $20,000 of the convertible Promissory Notes described in item 5. In addition, the Company issued 10,000 common shares as required under the terms of the original Promissory Note with Williams Ten LLC as described in item 5. The Company had 31,957,000 common shares issued and outstanding at March 31, 2017.

During the twelve month period ended March 31, 2018, the Company received a notice for the conversion of $157,902 of a convertible note described in item 5 and issued 15,790,245 common shares to the note holder. The Company received further notices for the conversion of $237,625 of the convertible Promissory Notes described in item 5 into 23,762,538 common shares. These shares were not issued from Treasury until April 19, 2018. The Company had 47,747,245 common shares issued and outstanding at March 31, 2018.

F-10

NOTE 9 – RELATED PARTY TRANSACTIONS

From inception through September 29, 2016, a Director loaned the Company $84,374 net of repayments to pay for incorporation costs, general and administrative expenses and professional fees, the acquisition of sales and distribution licenses and advances to Cure Pharmaceutical. On September 29, 2016, this amount was settled through the issuance of a convertible promissory note as described item 5 above. On September 29, 2017, the Director converted $39,373 of principal and $5,062 accrued interest into 4,443,565 shares of common stock. A new non-convertible unsecured, 6% promissory note for the remaining principal balance of $45,000 was issued. The new note matures in eighteen months.

On September 29, 2016, the Company entered into a consulting agreement with the Company’s sole officer and director for the provision of management and financial services. This agreement called for a one time payment of $10,000 on signing of the agreement, and payments of $5,000 per month for six months, terminating on March 30, 2017. In addition, an amount of $5,000 for services provided in September, 2016 was payable on either the termination of the contract or completion of a minimum $500,000 financing. As of March 31, 2018, $33,350 had been paid and $14,150 was payable pursuant to this contract. In addition, if financing of greater than $200,000 is obtained during the term of this contract, the consultant agreed to exchange 21,000,000 shares registered in his name for 6,000,000 newly issued restricted shares. The threshold of $200,000 in financing during the term of the agreement was not met and therefore the share exchange did not take place.

NOTE 10 – SUBSEQUENT EVENTS

On December 30, 2016, the Company received $30,000 from a third party as a subscription for 3,000,000 common shares at $0.01 per share. These shares were issued to the subscribers on April 19, 2018.

During the three month period ended September 30, 2017, the Company received promissory note conversion notices for the issuance of 39,552,783 common shares. 15,790,245 of these shares were issued on October 9, 2017. The balance of 23,762,528 shares were issued to the subscribers on April 19, 2018.

On April 10, 2018, the Company entered into a Memorandum of Understanding with Dr. Judy Pham wherein Dr. Pham agreed to provide up to $100,000 in equity financing to assist with a corporate reorganization including bringing the Company current in its regulatory filings. On completion of the reorganization and the issuance of capital stock in consideration for the funds advanced, Dr. Pham will be the owner of 85% of the issued and outstanding common shares of the Company. As of July 5, 2018, Dr. Pham had advanced $75,770 to the Company pursuant to this Memorandum of Understanding

In accordance with ASC 855-10, the Company has analyzed its operations from March 31, 2018 to August 6, 2018 and has determined that it has no other material subsequent events to disclose in these financial statements.

END OF NOTES TO FINANCIAL STATEMENTS

F-11

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

Based on an evaluation as of the date of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as required by Exchange Act Rule 13a-15. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2018 to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, to allow timely decisions regarding required disclosure.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate control over financial reporting (as defined in Rule 13a-15(f) promulgated under the Exchange Act. Our management assessed the effectiveness of our internal control over financial reporting as of March 31, 2018. In making this assessment management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the criteria in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013) (COSO). Our management has concluded that, as of March 31, 2018, our internal control over financial reporting is effective based on these criteria.

Changes in Internal Control and Financial Reporting

There has been no change in our internal control over financial reporting identified in connection with our evaluation we conducted of the effectiveness of our internal control over financial reporting as of March 31, 2018, that occurred during our fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only management’s report in this annual report.

PART III

Item 10. Directors, Executive Officers and Corporate Governance

DIRECTORS AND EXECUTIVE OFFICERS

The name, age and titles of our executive officer and director is as follows:

Name and Address of Executive

Officer and/or Director

Age

Position

Alan M. Smith

6501 E. Greenway Pkwy #103-412

Scottsdale, AZ 85254

President, Treasurer, Secretary and Director

(Principal Executive, Financial and Accounting Officer)

Effective October 16, 2014, Homero Giovanni Penaherrera Zavala (“Mr. Zavala”) resigned from his positions as the current President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director of the Company. Mr. Zavala’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, practices, or otherwise.

On October 16, 2014, Alan Smith (“Mr. Smith”) was appointed to serve as the Company’s President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer, and Director of the Company to serve until the next annual meeting or until his successor is duly appointed. On October 16, 2014, Mr. Smith accepted such appointment. As of March 31, 2018, Mr. Smith owned 43.98% of the outstanding shares of our common stock (65.71% as at March 31, 2017).

During the past five years, Alan Smith, as President and CEO of Evolution Equities Corporation, has provided independent financial consulting services to a variety of startup and development stage companies in the technology, resource and consumer products sectors. These services have included corporate reorganizations and restructuring, the development of internal systems and controls and assistance with financing in both the private and public markets. From March 2014, Mr. Smith has acted as an officer and director of Mountain High Acquisitions Corp. (MYHI), a publicly held Colorado corporation. Additionally, Mr. Smith has been an active investor in a number of startup ventures while managing his own personal equity portfolio. Mr. Smith is a Chartered Accountant and has provided audit, tax and financial consulting services to a wide variety of small to medium sized companies during his 35 year career. Mr. Smith obtained his Chartered Accountant designation in 1978 from the Institute of Chartered Accountants of Ontario. He was also a member of the Institute of Chartered Accountants of British Columbia from 1980 until his retirement in 1999. Additionally, Mr. Smith earned a Master’s Degree in Business Administration in 1975 from Queen’s University at Kingston, Ontario and a Bachelor of Applied Science (Civil Engineering) in 1973, also from Queen’s University.

During the past ten years, Mr. Smith has not been the subject to any of the following events:

1. Any bankruptcy petition filed by or against any business of which Mr. Smith was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time.

2. Any conviction in a criminal proceeding or being subject to a pending criminal proceeding.

3. An order, judgment, or decree, not subsequently reversed, suspended or vacated, or any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting Mr. Smith’s involvement in any type of business, securities or banking activities.

4. Found by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission or the Commodity Future Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

5. Was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right to engage in any activity described in paragraph (f)(3)(i) of this section, or to be associated with persons engaged in any such activity;

6. Was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;

7. Was the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

i. Any Federal or State securities or commodities law or regulation; or

ii.Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or

iii Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

8. Was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

17 | Page

AUDIT COMMITTEE

We do not have an audit committee financial expert. We do not have an audit committee financial expert because we believe the cost related to retaining a financial expert at this time is prohibitive. Further, because we have no operations at the present time, we believe the services of a financial expert are not warranted.

ITEM 11. EXECUTIVE COMPENSATION

The table below summarizes all compensation awarded to, earned by, or paid to our executive officers by any person for all services rendered in all capacities to us for the fiscal period from our incorporation on December 20, 2012 to March 31, 2018.

SUMMARY COMPENSATION TABLE

Summary Compensation Table

Name and	Year		Salary		Bonus		Stock		Option		Non-Equity Incentive		All Other		Total
Principal			($)		($)		Awards		Awards		Plan		Compensation		($)
Position							($)		($)		Compensation		($)
											($)
Homero Giovanni Penaherrera Zavala,		2012
President, Secretary		2013		-0-		-0-		-0-		-0-		-0-		-0-		-0-
and Treasurer		2014

Alan Smith,		2014		-0-		-0-		-0-		-0-		-0-		-0-		-0-
President Secretary		2015		-0-		-0-		-0-		-0-		-0-		-0-		-0-
and Treasurer		2016		-0-		-0-		-0-		-0-		-0-		-0-		-0-
		2017		-0-		-0-		-0-		-0-		-0-	$	26,585	$	26,585
		2018		-0-		-0-		-0-		-0-		-0-	$	6,765	$	6,765

There are no current employment or consulting agreements between the company and its officer.

As of March 31, 2018, we had no pension plans or compensatory plans or other arrangements which provide compensation in the event of a termination of employment or a change in our control.

18 | Page

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table provides certain information regarding the ownership of our common stock, as of the date of the filing of this annual report by:

	•		each of our executive officers;
	•		each director;
	•		each person known to us to own more than 5% of our outstanding common stock; and
	•		all of our executive officers and directors and as a group.

Title of Class	Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership	Percentage

Common Stock	Alan Smith 6501 E Greenway Pkwy #103-412 Scottsdale, AZ 95254	25,443,565 shares of common stock (direct)		34.14	%
All officers and directors (1 person)		25,443,565 shares of common stock		34.14	%

The percent of class is based on 74,509,883 shares of common stock issued and outstanding as of the date of this annual report.

ITEM 13. CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

During the year ended March 31, 2018, we had not entered into any transactions with our sole officer or director, or persons nominated for these positions, beneficial owners of 5% or more of our common stock, or family members of these persons wherein the amount involved in the transaction or a series of similar transactions exceeded the lesser of $120,000 or 1% of the average of our total assets for the last three fiscal years except as noted below.

Alan Smith, the Company’s sole director, is not independent under the rules of the NASDAQ stock market or Rule 10A-3 of the Exchange Act.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

During the fiscal year ended March 31, 2018, we incurred approximately $nil in fees to our principal independent accountants for professional services rendered in connection with the audit of our financial statements and for the quarterly reviews of our financial statements.

19 | Page

ITEM 15. EXHIBITS

The following exhibits are filed as part of this Annual Report.

Exhibits:

	Number		Description

	3.01		Articles of Incorporation - Filed with the SEC on July 29, 2013 as part of our Registration Statement on Form S-1.
	3.02		Bylaws - Filed with the SEC on July 29, 2013 as part of our Registration Statement on Form S-1.
	31.1		Certification of Principal Executive Officer and Principal Financial Officer, pursuant to SEC Rules 13a-14(a) and 15d-14(a), adopted pursuant Section 302 of the Sarbanes Oxley Act of 2002
	32.1		Certification of Chief Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
	101.INS		XBRL Instance Document
	101.SCH		XBRL Taxonomy Extension Schema Document
	101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
	101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
	101.LAB		XBRL Taxonomy Extension Label Linkbase Document
	101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.


	ALTAIR INTERNATIONAL CORP.

Dated: August 17, 2018	By: /s/ Alan M. Smith Alan M. Smith, President, Secretary and Treasurer

20 | Page

EX-31.1 2 atao0814form10kexh31_1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION

I, Alan M. Smith, certify that:

1.	I have reviewed this Annual Report on Form 10-K of Altair International Corp. (the “Company”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented ire this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

5.	I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: August 17, 2018

/s/ Alan M. Smith

Alan M. Smith

Chief Executive Officer

EX-31.2 3 atao0814form10kexh31_2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION

I, Alan M. Smith, certify that:

1.	I have reviewed this Annual Report on Form 10-K of Altair International Corp. (the “Company”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented ire this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

5.	I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: August 17, 2018

		/s/ Alan M. Smith
		Alan M. Smith
		Chief Financial Officer

EX-32.1 4 atao0814form10kexh32_1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Altair International Corp. (the “Company”) on Form 10-K for the period ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan M. Smith, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 17, 2018		/s/ Alan M. Smith
		Alan M. Smith
		Chief Executive Officer

EX-32.2 5 atao0814form10kexh32_2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Altair International Corp. (the “Company”) on Form 10-K for the period ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan M. Smith, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 17, 2018		/s/ Alan M. Smith
		Alan M. Smith
		Chief Financial Officer

EX-101.INS 6 atao-20180331.xml XBRL INSTANCE FILE 0001570937 2017-04-01 2018-03-31 0001570937 2018-08-17 0001570937 2018-03-31 0001570937 2017-03-31 0001570937 2016-04-01 2016-12-31 0001570937 us-gaap:CommonStockMember 2017-04-01 2018-03-31 0001570937 us-gaap:CommonStockMember 2017-03-31 0001570937 us-gaap:CommonStockMember 2018-03-31 0001570937 us-gaap:AdditionalPaidInCapitalMember 2017-04-01 2018-03-31 0001570937 us-gaap:AdditionalPaidInCapitalMember 2017-03-31 0001570937 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001570937 us-gaap:RetainedEarningsMember 2017-04-01 2018-03-31 0001570937 us-gaap:RetainedEarningsMember 2017-03-31 0001570937 us-gaap:RetainedEarningsMember 2018-03-31 0001570937 2015-03-31 0001570937 us-gaap:ConvertibleDebtMember 2015-03-06 0001570937 us-gaap:ConvertibleDebtMember 2017-04-01 2018-03-31 0001570937 2015-07-22 0001570937 2014-04-01 2015-03-31 0001570937 2016-01-01 2016-03-31 0001570937 2012-12-20 2016-09-29 0001570937 2016-09-29 0001570937 ATAO:ConvertibleNote1Member 2017-04-01 2018-03-31 0001570937 ATAO:ConvertibleNote1Member 2018-03-31 0001570937 ATAO:ConvertibleNote2Member 2017-04-01 2018-03-31 0001570937 ATAO:ConvertibleNote2Member 2018-03-31 0001570937 ATAO:ConvertibleNote3Member 2017-04-01 2018-03-31 0001570937 ATAO:ConvertibleNote3Member 2018-03-31 0001570937 ATAO:ConvertibleNote4Member 2017-04-01 2018-03-31 0001570937 ATAO:ConvertibleNote4Member 2018-03-31 0001570937 ATAO:ConvertibleNote5Member 2017-04-01 2018-03-31 0001570937 ATAO:ConvertibleNote5Member 2018-03-31 0001570937 ATAO:ConvertibleNote6Member 2017-04-01 2018-03-31 0001570937 ATAO:ConvertibleNote6Member 2018-03-31 0001570937 ATAO:ConvertibleNoteMember 2018-03-31 0001570937 ATAO:ConvertibleNote1Member 2016-09-29 0001570937 ATAO:ConvertibleNote2Member 2016-09-29 0001570937 ATAO:ConvertibleNote3Member 2016-09-29 0001570937 ATAO:ConvertibleNote4Member 2016-09-29 0001570937 ATAO:ConvertibleNote5Member 2016-09-29 0001570937 ATAO:ConvertibleNote6Member 2016-09-23 0001570937 2016-10-01 2017-03-30 0001570937 2016-09-01 2016-09-30 0001570937 ATAO:ConvertibleNote7Member 2017-04-01 2018-03-31 0001570937 ATAO:ConvertibleNote7Member 2018-03-31 0001570937 ATAO:ConvertibleNote7Member 2016-10-14 0001570937 us-gaap:CommonStockMember 2015-03-31 0001570937 us-gaap:AdditionalPaidInCapitalMember 2015-03-31 0001570937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-04-01 2018-03-31 0001570937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-03-31 0001570937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-03-31 0001570937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001570937 us-gaap:RetainedEarningsMember 2015-03-31 0001570937 us-gaap:FairValueInputsLevel3Member 2017-04-01 2018-03-31 0001570937 2018-04-19 0001570937 2018-04-10 2018-08-06 0001570937 2018-04-18 2018-04-19 0001570937 2016-03-31 0001570937 2016-04-01 2017-03-31 0001570937 2015-04-01 2016-03-31 0001570937 ATAO:ConvertibleNote4Member 2016-04-01 2017-03-31 0001570937 ATAO:ConvertibleNote1Member 2016-04-01 2017-03-31 0001570937 2016-04-01 2016-06-30 0001570937 us-gaap:CommonStockMember 2015-04-01 2016-03-31 0001570937 us-gaap:CommonStockMember 2016-04-01 2017-03-31 0001570937 us-gaap:CommonStockMember 2016-03-31 0001570937 us-gaap:AdditionalPaidInCapitalMember 2015-04-01 2016-03-31 0001570937 us-gaap:AdditionalPaidInCapitalMember 2016-04-01 2017-03-31 0001570937 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0001570937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-04-01 2016-03-31 0001570937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-04-01 2017-03-31 0001570937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-03-31 0001570937 us-gaap:RetainedEarningsMember 2015-04-01 2016-03-31 0001570937 us-gaap:RetainedEarningsMember 2016-04-01 2017-03-31 0001570937 us-gaap:RetainedEarningsMember 2016-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ALTAIR INTERNATIONAL CORP. 0001570937 10-K 2018-03-31 false --03-31 No No No Smaller Reporting Company FY 2018 74509883

0.001

75000000

47747245

31957000

29947000

47747245

31957000

29947000

NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS Organization and Description of Business   ALTAIR INTERNATIONAL CORP. (the “Company”) was incorporated under the laws of the State of Nevada on December 20, 2012. The Company’s physical address is 18934 N 92nd Way, Scottsdale, AZ 85255. The Company is in the development stage as defined under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915-205 "Development-Stage Entities.”   On November 11, 2014, the Company entered into a strategic alliance with Cure Pharmaceutical Corporation (“CURE”), a California company engaged in the development of oral thin film (“OTF”) for the delivery of nutraceutical, over-the-counter and prescription products. Initially this alliance was comprised of an Exclusive License and Distribution Agreement for CURE’s Sildenafil (commonly known as Viagra) Products throughout Asia, Brazil, the Middle East and Canada acquired at a cost of $200,000 while a joint venture agreement for the procurement of converting and packaging equipment specific for oral thin film products was proposed through a Letter of Intent. In addition, Altair and Cure agreed to enter into further joint ventures or other business relationships for the purpose of completing the development and marketing of additional products, and for license and distribution agreements for additional Cure products such as aspirin, sleep-aid, topical muscle and joint pain relief, and electrolytes delivered through OTF or other methods. Altair advanced $360,000 to CURE in this regard.   On September 23, 2016, the Company and CURE agreed to terminate the Exclusive License and Distribution Agreement for CURE’s Sildenafil Products due to unanticipated costs of obtaining regulatory approvals for the introduction of these pharmaceutical products into the licensed markets. In its place, the Company and CURE agreed to replace it with an Exclusive License and Distribution Agreement for a family of sports related nutraceutical products including a topical active for joint and muscle pain and OTF products for delivery of electrolyte, energy, sleep and recovery actives. The Company was to become the exclusive worldwide distributor for these products. The fee for this new sport products agreement was $560,000, comprised of the $200,000 fee paid for the Sildenafil agreement and the $360,000 advanced as a deposit for future license and distribution agreements. The agreement called for minimum orders of the products by Altair of $1,500,000 in the twenty-four months from the date of signing. As of June 29, 2018, the Company has been unable to generate any sales of the products due to a lack of working capital and the human resources required to introduce the products to market. The Company anticipates that it will not meet the minimum order requirements for the initial 24 month period and accordingly wrote off its $560,000 investment in the agreement in these financial statements for the year ended March 31, 2017.   The Company is currently engaged in identifying and assessing new business opportunities.   The Company had previously planned to commence operations in the architectural field and to be responsible for the concept architectural vision of future private and public buildings as well as municipal organized public areas. This plan was abandoned in the 2015 fiscal year in favor of the business operations described above.   Since inception (December 20, 2012) through March 31, 2018, the Company has not generated any revenue and has accumulated losses of $825,818.   In management’s opinion all adjustments necessary for a fair statement of the results for the interim periods have been made, and that all adjustments have been made to maintain the books in accordance with GAAP. Furthermore, sufficient disclosures have been made in order to ensure that the interim financial statements will not be misleading.

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation   The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the years ending March 31, 2018 and 2017.   Cash and Cash Equivalents   For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.   The Company's bank accounts are deposited in insured institutions. The funds are insured up to $250,000. At March 31, 2018 the Company's bank deposits did not exceed the insured amounts.   Basic and Diluted Income (Loss) Per Share   The Company computes loss per share in accordance with “ASC-260”, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period.  Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive.   Income Taxes   The Company follows the liability method of accounting for income taxes.  Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences).  The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.   Fair Value of Financial Instruments   FASB ASC 820 "Fair Value Measurements and Disclosures" establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.   These tiers include:   Level 1: defined as observable inputs such as quoted prices in active markets;   Level 2:  defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and   Level 3:  defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.   The carrying amounts of financial assets and liabilities, such as cash and accrued liabilities approximate their fair values because of the short maturity of these instruments.   Use of Estimates   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period.  Actual results could differ from those estimates.   Reclassifications   Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the financial statements for the year ended March 31, 2018.

Basis of Presentation   The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the years ending March 31, 2018 and 2017.

Cash and Cash Equivalents   For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.   The Company's bank accounts are deposited in insured institutions. The funds are insured up to $250,000. At March 31, 2018 the Company's bank deposits did not exceed the insured amounts.

Basic and Diluted Income (Loss) Per Share   The Company computes loss per share in accordance with “ASC-260”, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period.  Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive.

Income Taxes   The Company follows the liability method of accounting for income taxes.  Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences).  The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Fair Value of Financial Instruments   FASB ASC 820 "Fair Value Measurements and Disclosures" establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.   These tiers include:   Level 1: defined as observable inputs such as quoted prices in active markets;   Level 2:  defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and   Level 3:  defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.   The carrying amounts of financial assets and liabilities, such as cash and accrued liabilities approximate their fair values because of the short maturity of these instruments.

Use of Estimates   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

250000

NOTE 8 – COMMON STOCK   The Company has 75,000,000 common shares authorized with a par value of $0.001 per share.   The Company had 29,947,000 common shares issued and outstanding at March 31, 2016.   During the twelve month period ended March 31, 2017 the Company issued 2,000,000 common shares on the conversion of $20,000 of the convertible Promissory Notes described in item 5. In addition, the Company issued 10,000 common shares as required under the terms of the original Promissory Note with Williams Ten LLC as described in item 5. The Company had 31,957,000 common shares issued and outstanding at March 31, 2017.   During the twelve month period ended March 31, 2018, the Company received a notice for the conversion of $157,902 of a convertible note described in item 5 and issued 15,790,245 common shares to the note holder. The Company received further notices for the conversion of $237,625 of the convertible Promissory Notes described in item 5 into 23,762,538 common shares. These shares were not issued from Treasury until April 19, 2018. The Company had 47,747,245 common shares issued and outstanding at March 31, 2018.

NOTE 9 – RELATED PARTY TRANSACTIONS   From inception through September 29, 2016, a Director loaned the Company $84,374 net of repayments to pay for incorporation costs, general and administrative expenses and professional fees, the acquisition of sales and distribution licenses and advances to Cure Pharmaceutical.  On September 29, 2016, this amount was settled through the issuance of a convertible promissory note as described item 5 above. On September 29, 2017, the Director converted $39,373 of principal and $5,062 accrued interest into 4,443,565 shares of common stock. A new non-convertible unsecured, 6% promissory note for the remaining principal balance of $45,000 was issued. The new note matures in eighteen months.   On September 29, 2016, the Company entered into a consulting agreement with the Company’s sole officer and director for the provision of management and financial services. This agreement called for a one time payment of $10,000 on signing of the agreement, and payments of $5,000 per month for six months, terminating on March 30, 2017. In addition, an amount of $5,000 for services provided in September, 2016 was payable on either the termination of the contract or completion of a minimum $500,000 financing. As of March 31, 2018, $33,350 had been paid and $14,150 was payable pursuant to this contract. In addition, if financing of greater than $200,000 is obtained during the term of this contract, the consultant agreed to exchange 21,000,000 shares registered in his name for 6,000,000 newly issued restricted shares. The threshold of $200,000 in financing during the term of the agreement was not met and therefore the share exchange did not take place.

NOTE 10 – SUBSEQUENT EVENTS   On December 30, 2016, the Company received $30,000 from a third party as a subscription for 3,000,000 common shares at $0.01 per share. These shares were issued to the subscribers on April 19, 2018.   During the three month period ended September 30, 2017, the Company received promissory note conversion notices for the issuance of 39,552,783 common shares. 15,790,245 of these shares were issued on October 9, 2017. The balance of 23,762,528 shares were issued to the subscribers on April 19, 2018.   On April 10, 2018, the Company entered into a Memorandum of Understanding with Dr. Judy Pham wherein Dr. Pham agreed to provide up to $100,000 in equity financing to assist with a corporate reorganization including bringing the Company current in its regulatory filings. On completion of the reorganization and the issuance of capital stock in consideration for the funds advanced, Dr. Pham will be the owner of 85% of the issued and outstanding common shares of the Company. As of July 5, 2018, Dr. Pham had advanced $75,770 to the Company pursuant to this Memorandum of Understanding In accordance with ASC 855-10, the Company has analyzed its operations from March 31, 2018 to August 6, 2018 and has determined that it has no other material subsequent events to disclose in these financial statements.

308134

100004

10960

10896

126612

66766

27673

6744

100000

NOTE 5 – PROMISSORY NOTES   On March 6, 2015, the Company executed a convertible promissory note for $100,000 with Williams Ten, LLC (“Williams”). The note was due in ninety days, had a $10,000 one-time interest payment due at maturity and required the issuance of 10,000 shares of common stock. Any unpaid principal and interest at the end of the term was convertible into shares of common stock at 50% of the average closing price for the ten days prior to the end of the term of the note. The fair value of the common stock issued was determined to be $9,091 based on its fair value relative to the fair value of the debt issued. This amount was recorded as a debt discount and was to be amortized utilizing the interest method of accretion over the term of the note. In addition, due to the variable nature of the conversion feature which has no explicit limit on the number of shares that could be required to be issued, the company bifurcated the conversion feature and accounted for it as a derivative liability. The Company recorded the derivative liability at its fair value of $100,004 based on the Black Scholes Merton pricing model and a corresponding debt discount of $90,909 and derivative expense charge of $9,095. On September 29, 2016, Williams agreed to cancel this Promissory Note and accept a new Convertible Promissory Note in the amount of $121,000, which included all accrued interest and penalties. This Convertible Promissory Note bears interest at the rate of 6.00% per annum and has a one-year term. The Holder is entitled to convert any or all of the principal amount of this Note and any accrued interest, late fee, and extension fee, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 as is obtained by dividing the entire principal amount of this Note plus any accrued interest by $0.01 per share. On October 3, 2016, Williams converted $10,000 of the principal balance into 1,000,000 shares of common stock. On September 29, 2017, Williams converted the remaining principal of $111,000 plus $6,691 of accrued interest into 11,769,123 shares of common stock. The Company recognized a gain of $15,215 on conversion of the note and a gain on the fair value of the derivative of $16,504. As of September 30, 2017, this note had a $0 balance.   On September 23, 2016, the Company issued two Convertible Promissory Notes in the principal amounts of $10,000 and $25,000 to Enpos Sports, LLC (“Enpos”) as consideration for $35,000 in cash advances to the Company. These convertible Promissory Notes bear interest at the rate of 6.00% per annum and have a one-year term. The Holder is entitled to convert any or all of the principal amount of these Notes and any accrued interest, late fees, and extension fees, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 as is obtained by dividing the entire principal amount of the Notes plus any accrued interest at the lesser of (i) 70% of the lowest closing bid price over the 5 trading days prior to conversion or (ii) $0.10 per share. Due to the variable nature of the conversion feature which has no explicit limit on the number of shares that could be required to be issued, the company bifurcated the conversion feature and accounted for it as a derivative liability on both notes. The Company recorded the derivative liability at its fair value of $27,673 based on the Black Scholes Merton pricing model and a corresponding debt discount of $27,673 to be amortized utilizing the interest method of accretion over the term of the note. On September 29, 2017, Enpos converted the principal of $35,000 plus $2,135 of accrued interest into 3,713,452 shares of common stock. The Company recognized a gain of $4,766 on conversion of the note, a gain on the fair value of the derivative of $5,197 and amortized the remaining debt discount of $6,445 to interest expense. As of September 30, 2017, this note had a $0 balance.   On September 29, 2016, the Company issued a Convertible Promissory Note in the principal amount of $13,850 to Strips Nutrition, Inc. (“Strips”) as consideration for $13,850 in cash advances to the Company. This Convertible Promissory Note bears interest at the rate of 6.00% per annum and has a one-year term. The Holder is entitled to convert any or all of the principal amount of this Note and any accrued interest, late fee, and extension fee, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 as is obtained by dividing the entire principal amount of this Note plus any accrued interest by $0.01 per share. The company bifurcated the conversion feature and accounted for it as a derivative liability. The Company recorded the derivative liability at its fair value of $10,960 based on the Black Scholes Merton pricing model and a corresponding debt discount of $10,960 to be amortized utilizing the interest method of accretion over the term of the note. On September 29, 2017, Strips converted the principal of $13,850 plus $831 of accrued interest into 1,468,100 shares of common stock. The Company recognized a gain of $1,886 on conversion of the note, a gain on the fair value of the derivative of $2,056 and amortized the remaining debt discount of $2,733 to interest expense. As of September 30, 2017, this note had a $0 balance.   On September 29, 2016, the Company issued a Convertible Promissory Note in the principal amount of $13,768.89 to Mr. Fred Lee as consideration for $13,768.89 in travel expenses incurred in assessing distribution opportunities in Asia for the Company. This Convertible Promissory Note bears interest at the rate of 6.00% per annum and has a one-year term. The Holder is entitled to convert any or all of the principal amount of this Note and any accrued interest, late fee, and extension fee, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 (the “Common Stock”) as is obtained by dividing the entire principal amount of this Note plus any accrued interest by $0.01 per share. The company bifurcated the conversion feature and accounted for it as a derivative liability. The Company recorded the derivative liability at its fair value of $10,896 based on the Black Scholes Merton pricing model and a corresponding debt discount of $10,896 to be amortized utilizing the interest method of accretion over the term of the note. On September 29, 2017, Mr. Lee converted the principal of $13,768.89 plus $826 of accrued interest into 1,459,502 shares of common stock. The Company recognized a gain of $1,887 on conversion of the note, a gain on the fair value of the derivative of $2,047 and amortized the remaining debt discount of $2,716 to interest expense. As of September 30, 2017, this note had a $0 balance.   On September 29, 2016, the Company issued a Convertible Promissory Note in the principal amount of $160,000 to Mr. Brent McMahon as consideration for $160,000 in cash advances to the Company. This Convertible Promissory Note bears interest at the rate of 6.00% per annum and has a one-year term. The Holder is entitled to convert any or all of the principal amount of this Note and any accrued interest, late fee, and extension fee, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 (the “Common Stock”) as is obtained by dividing the entire principal amount of this Note plus any accrued interest by $0.01 per share. The company bifurcated the conversion feature and accounted for it as a derivative liability. The Company recorded the derivative liability at its fair value of $126,612 based on the Black Scholes Merton pricing model and a corresponding debt discount of $126,612 to be amortized utilizing the interest method of accretion over the term of the note. On October 3, 2016, Mr. McMahon converted $10,000 of the principal balance into 1,000,000 shares of common stock. On September 29, 2017, Mr. McMahon converted the remaining principal of $150,000 plus $7,902 of accrued interest into 15,790,245 shares of common stock. The Company recognized a gain of $20,453 on conversion of the note, a gain on the fair value of the derivative of $22,303 and amortized the remaining debt discount of $31,567 to interest expense. As of September 30, 2017, this note had a $0 balance.   On September 29, 2016, the Company issued a Convertible Promissory Note in the principal amount of $84,373.25 to Evolution Equities Corporation (“Evolution”), a related company, as consideration for $84,373.25 in expenses paid on behalf of the Company. This Convertible Promissory Note bears interest at the rate of 6.00% per annum and has a one-year term. The Holder is entitled to convert any or all of the principal amount of this Note and any accrued interest, late fee, and extension fee, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 (the “Common Stock”) as is obtained by dividing the entire principal amount of this Note plus any accrued interest by $0.01 per share. The company bifurcated the conversion feature and accounted for it as a derivative liability. The Company recorded the derivative liability at its fair value of $66,766 based on the Black Scholes Merton pricing model and a corresponding debt discount of $66,766 to be amortized utilizing the interest method of accretion over the term of the note. On September 29, 2017, Evolution converted $39,373 of principal and $5,062 accrued interest into 4,443,565 shares of common stock. A new non-convertible unsecured, 6% promissory note for the remaining principal balance of $45,000 was issued. The new note matures in eighteen months. The Company recognized a gain of $17,898 on conversion of the note, a gain on the fair value of the derivative of $5,854 and amortized the remaining debt discount of $16,645 to interest expense. As of September 30, 2017, this note had a $0 balance.   On October 14, 2016, the Company issued a Convertible Promissory Note in the principal amount of $8,594.48 to Enpos Sports, LLC (“Enpos”) as consideration for $8,594.48 in cash advances to the Company. The convertible Promissory Note bears interest at the rate of 6.00% per annum and has a one-year term. The Holder is entitled to convert any or all of the principal amount of this Note and any accrued interest, late fees, and extension fees, if applicable, into such number of shares of the Company’s shares of common stock, par value $.0001 (the “Common Stock”) as is obtained by dividing the entire principal amount of the Note plus any accrued interest at the lesser of (i) 70% of the lowest closing bid price over the 5 trading days prior to conversion or (ii) $0.10 per share. Due to the variable nature of the conversion feature which has no explicit limit on the number of shares that could be required to be issued, the company bifurcated the conversion feature and accounted for it as a derivative liability. The Company recorded the derivative liability at its fair value of $6,744 based on the Black Scholes Merton pricing model and a corresponding debt discount of $6,744 to be amortized utilizing the interest method of accretion over the term of the note. On September 29, 2017, Enpos converted the principal of $8,594.48 plus $494 of accrued interest into 908,896 shares of common stock. The Company recognized a gain of $1,322 on conversion of the note, a gain on the fair value of the derivative of $1,278 and amortized the remaining debt discount of $1,940 to interest expense. As of September 30, 2017, this note had a $0 balance.   A summary of outstanding convertible notes as of March 31, 2018, is as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid; padding-left: -10pt">Note Holder</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Issue Date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Maturity Date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stated Interest Rate</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Principal Balance 03/31/2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 33%; text-align: left; padding-left: 0pt">Enpos Sports, LLC</td><td style="width: 2%"> </td> <td style="width: 15%; text-align: center; padding-left: 5.4pt">9/23/2016</td><td style="width: 2%"> </td> <td style="width: 15%; text-align: center; padding-left: 5.4pt">9/23/2017</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 10%; text-align: center">6%</td><td style="width: 1%; text-align: center"></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">—  </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Williams Ten, LLC</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2016</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2017</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">6%</td><td style="text-align: center"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Strips Nutrition, Inc.</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2016</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2017</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">6%</td><td style="text-align: center"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Mr. Fred Lee</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2016</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2017</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">6%</td><td style="text-align: center"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Mr. Brent McMahon</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2016</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2017</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">6%</td><td style="text-align: center"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Evolution Equities Corporation</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2016</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2017</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">6%</td><td style="text-align: center"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Enpos Sports, LLC</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">10/14/2016</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">10/14/2017</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="text-align: center">6%</td><td style="padding-bottom: 1pt; text-align: center"></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Total</td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   A summary of the activity of the derivative liability for the notes above is as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; text-align: left; padding-left: 0pt">Balance at March 31, 2016</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">100,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Increase to derivative due to new issuances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">249,651</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Derivative (gain) due to mark to market adjustment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(41,517</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Balance at March 31, 2017</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">308,134</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Derivative (gain) due to conversion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(63,417</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Derivative (gain) due to mark to market adjustment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(244,717</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Balance at March 31, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   A summary of quantitative information about significant unobservable inputs (Level 3 inputs) used in measuring the Company’s derivative liabilities that are categorized within Level 3 of the fair value hierarchy as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Inputs</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">September 30, 2017</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Initial Valuation</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 42%; text-align: justify">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 25%; text-align: right">.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 25%; text-align: right">.01</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Conversion price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Volatility (annual)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74.2%</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248.1% - 248.6%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.06%</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">.59% - .60%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Years to maturity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> </table>   The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.

100000

13850

13769

160000

84373

35000

8594

10000

0.50

9091

90909

10960

10896

126612

66766

27673

6744

9095

NOTE 2 - GOING CONCERN   These financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.  The Company has incurred losses since inception resulting in an accumulated deficit of $825,818 as of March 31, 2018 and further losses are anticipated in the development of its business raising substantial doubt about the Company’s ability to continue as a going concern.  The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and/or private placement of common stock.

NOTE 4 – SALES AND DISTRIBUTION LICENSE   On November 26, 2014, the Company entered into a license and distribution agreement with Cure Pharmaceutical Corporation (“Cure”) for the exclusive rights to distribute and sell in certain defined territories any product produced and supplied by Cure that contains Sildenafil delivered through an oral thin film. The defined territories included Asia, Brazil, the Middle East and Canada. For the sake of clarity, Asia was further defined as India, China, Malaysia, Indonesia, Taiwan, Japan, Philippines, and those other countries dependent on China’s SDA certification for their approval protocol of the Products. There was no expiry date to this agreement. The agreement required that the Company pay to Cure a fee in the aggregate amount of $200,000, payable in two equal $100,000 instalments. The Company completed the purchase of the license in the 2015 fiscal year.   On September 23, 2016, the Company and CURE agreed to terminate the Exclusive License and Distribution Agreement for CURE’s Sildenafil Products due to unanticipated costs of obtaining regulatory approvals for the introduction of these pharmaceutical products into the Asian markets and to replace it with an Exclusive License and Distribution Agreement for a family of sports related nutraceutical products including a topical active for joint and muscle pain and OTF products for delivery of electrolyte, energy, sleep and recovery actives, The Company became the exclusive worldwide distributor for these products. The fee for this new Exclusive License and Distribution Agreement was $560,000, comprised of the $200,000 fee paid for the Sildenafil agreement and the $360,000 advanced as a deposit for future license and distribution agreements. This Agreement has a ten year term and requires minimum product orders of $1,500,000 in the first 24 months from the effective date of the Agreement and $1,500,000 for each year thereafter. As of June 29, 2018, the Company had been unable to generate any sales of the products due to a lack of working capital and the human resources required to introduce the products to market. The Company anticipates that it will not meet the minimum order requirements for the initial 24 month period and accordingly wrote off its $560,000 investment in the agreement as at March 31, 2017 in these financial statements.

11000

NOTE 6 – LOANS PAYABLE   On July 22, 2015, the Company obtained a loan from a third party in the amount of $25,000. This loan was non-interest bearing, was unsecured and had no fixed terms of repayment. The loan was repaid in its entirety on September 29, 2016.   During the fiscal year ended March 31, 2016, the Company obtained a loan from a third party in the amount of $4,175. A further $9,990 was loaned to the Company in the 2017 fiscal year. This loan is non-interest bearing, is unsecured and has no fixed terms of repayment.   In the three month period ended March 31, 2016, the Company obtained loans from a third party in the total amount of $11,350. In the three month period ended June 30, 2016, the Company received a further $2,500 in loans from this same third party. These loans totaling $13,850 were non-interest bearing, unsecured and had no fixed terms of repayment. On September 29, 2016 these loans were settled through the issuance of a Convertible Promissory Note as described in item 5(2) above.

25000

360000

11350

2500

84374

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid; padding-left: -10pt">Note Holder</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Issue Date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Maturity Date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stated Interest Rate</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Principal Balance 03/31/2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt; width: 33%">Enpos Sports, LLC</td><td style="width: 2%"> </td> <td style="text-align: center; padding-left: 5.4pt; width: 15%">9/23/2016</td><td style="width: 2%"> </td> <td style="text-align: center; padding-left: 5.4pt; width: 15%">9/23/2017</td><td style="width: 2%"> </td> <td style="text-align: center; width: 1%"> </td><td style="text-align: center; width: 10%">6%</td><td style="text-align: center; width: 1%"></td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 15%">—  </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Williams Ten, LLC</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2016</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2017</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">6%</td><td style="text-align: center"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Strips Nutrition, Inc.</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2016</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2017</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">6%</td><td style="text-align: center"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Mr. Fred Lee</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2016</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2017</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">6%</td><td style="text-align: center"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Mr. Brent McMahon</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2016</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2017</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">6%</td><td style="text-align: center"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Evolution Equities Corporation</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2016</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">9/29/2017</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">6%</td><td style="text-align: center"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Enpos Sports, LLC</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">10/14/2016</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">10/14/2017</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="text-align: center">6%</td><td style="padding-bottom: 1pt; text-align: center"></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Total</td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt; width: 77%">Balance at March 31, 2016</td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 20%">100,000</td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Increase to derivative due to new issuances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">249,651</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Derivative (gain) due to mark to market adjustment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(41,517</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Balance at March 31, 2017</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">308,134</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Derivative (gain) due to conversion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(63,417</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Derivative (gain) due to mark to market adjustment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(244,717</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Balance at March 31, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

560000 360000 P10Y 1500000 1500000

2016-09-29

2016-09-23

2016-10-14

2017-09-29

2017-09-23

2017-10-14

0.06

45000 121000 0.06 0.06 33350 14150 10000 5000 5000 111000 13850 13769 150000 39373 35000 8594 10000 10000 11769123 1468100 1459502 15790245 4443565 3713452 908896 1000000 1000000

0.06

15790245 2000000 157902 20000 10000

15790245

23762638

2000000

NOTE 7 – SHARE SUBSCRIPTIONS   On December 30, 2016, the Company received $30,000 from a third party as a subscription for 3,000,000 common shares at $0.01 per share. These shares were issued to the subscribers on April 19, 2018.

Reclassifications   Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the financial statements for the year ended March 31, 2018.

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Inputs</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">September 30, 2017</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Initial Valuation</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; width: 42%">Stock price</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 25%">.01</td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 25%">.01</td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Conversion price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Volatility (annual)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74.2%</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248.1% - 248.6%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.06%</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">.59% - .60%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Years to maturity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> </table>

200000 200000

249651

-244717

-41517

0.01

.01

2.481

.742

2.486

0.0106

.0060

.0059

P3M

P1Y

3000000

75770

560000

9990 4175 -63417 6691 831 826 7902 5062 2135 494 15215 1886 1877 20453 17898 4766 1322 16504 2056 2047 22303 5854 5197 1278

2733

2716

31567

16645

6445

1940

3000000 0

7523

5422

7523

78467

648763

78467

648763

45000

51082

241217

1354

12575

14165

17948

21590

7523

-78392

-641240

31957

47747

289940

432052

-993137

-825818

-65745

29645

7146

30000

267627

-102536

45434

29947

271850

-256363

-825818

-993137

267627

30000

432052

289940

47747

31957

137008

138038

244717

41517

63417

3807

80253

167319

-736774

-153827

-736774

167319

-736774

39441144

30902589

.004

-0.024

31957000

47747245

29645000

29947000

302000

265006

302

264704

157902

15790

142112

20000

2000

18000

10000

100

237627 237627 30000 30000

-7448

-58983

124287 125364

-244717

-41517

-12722

-12674

3642

-21270

61084

30000

12510

43594

425529 23943 39373 332213 30000 186935 -249651 436586 124287 349651 252896 4227 308135 4227 55239

-7448

2101

EX-101.SCH 7 atao-20180331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENT OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENTS OF STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND BUSINESS OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SALES AND DISTRIBUTION LICENSE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PROMISSORY NOTES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - LOANS PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - SHARE SUBSCRIPTIONS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - COMMON STOCK link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - PROMISSORY NOTES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - ORGANIZATION AND BUSINESS OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SALES AND DISTRIBUTION LICENSE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - PROMISSORY NOTES - Summary of outstanding convertible notes (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - PROMISSORY NOTES - Summary of activity of derivative liability for convertible notes (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - PROMISSORY NOTES - Summary of quantitative information about significant unobservable inputs (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - PROMISSORY NOTES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - LOANS PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SHARE SUBSCRIPTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - COMMON STOCK (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 atao-20180331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 atao-20180331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 atao-20180331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Shares Additional Paid-In Capital Accumulated Deficit Debt Instrument [Axis] Williams Ten, LLC original note Williams Ten, LLC new note Strips Nutrition, Inc. Mr. Fred Lee Mr. Brent McMahon Evolution Equities Corporation Enpos Sports, LLC (1) Totals Enpos Sports, LLC (2) Common Stock Common Stock Subscribed Fair Value, Hierarchy [Axis] Initial Valuation Capital Stock Subscribed Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Total current assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable Loans payable Interest payable Promissory notes due to third parties Promissory note due to related party Derivative liability Total current liabilities Total Liabilities Stockholders' Equity (Deficit) Common Stock, $0.001 par value, 75,000,000 shares authorized; 47,747,245 shares issued and outstanding at March 31, 2018 (31,957,000 at March 31, 2017) Additional paid-in capital Common Stock subscribed Accumulated deficit Total stockholders' equity (deficit) Total liabilities and stockholders' equity (deficit) Common stock, par value Common stock, authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] Expenses Total General and Administrative expenses Write off of Sales and Distrubtion Licenses Gain on conversion of debt Derivative expense Interest expense Loss (gain) before income taxes Income taxes Net loss (gain) Loss (gain) per share - Basic Weighted Average Shares - Basic Statement [Table] Statement [Line Items] Beginning balance, shares Beginning balance, amount Common shares issued for cash, shares Common shares issued for cash, amount Common shares issued on conversion of Promissory Notes, shares Common shares issued on conversion of Promissory Notes, amount Common shares issued for debt, shares Common shares issued for debt, amount Common shares subscribed Net income (loss) Ending balance, shares Ending balance, amount Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net gain (loss) Adjustment to reconcile net loss to net cash used in operating activities: Changes in Accounts payable Changes in Interest payable Changes in Fair value of derivative liabilities Changes in Debt discount Cash Used In Operating Activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from Promissory Notes issued Proceeds from Loans Proceeds from common stock subscriptions Cash provided by financing activities NET INCREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS Beginning of year End of year Supplemental disclosures of cash flow information Taxes paid Interest paid Non-Cash Financing and Investing Activities Capital Stock subscribed for Conversion of loans from third parties Capital Stock subscribed for Conversion of Promissory Notes to third parties Capital Stock subscribed for Conversion of Promissory Note to related party Capital Stock subscribed for Accrued Interest on Promissory Notes Total Capital Stock subscribed Promissory Notes issued in settlement of loans Debt discount on issuance of Promissory Notes Promissory Notes issued, net Interest expense - debt discount in period Derivative Liability on issuance of Promissory Notes Reduction of derivative liability in period Reduction of derivative liability - mark to market on conversion of Promissory Notes Reduction of derivative liability in period, total Accounting Policies [Abstract] ORGANIZATION AND BUSINESS OPERATIONS Organization, Consolidation and Presentation of Financial Statements [Abstract] GOING CONCERN SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Other Income and Expenses [Abstract] SALES AND DISTRIBUTION LICENSE Debt Disclosure [Abstract] PROMISSORY NOTES Payables and Accruals [Abstract] LOANS PAYABLE Notes to Financial Statements SHARE SUBSCRIPTIONS Stockholders' Equity Note [Abstract] COMMON STOCK Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Cash and Cash Equivalents Basic and Diluted Income (Loss) Per Share Income Taxes Fair Value of Financial Instruments Use of Estimates Reclassifications Promissory Notes Summary of outstanding convertible notes Summary of activity of derivative liability for convertible notes Summary of quantitative information about significant unobservable inputs Organization And Business Operations Cost of acquiring Exclusive License and Distribution Agreement Cash advanced to CURE Fee paid for new Exclusive License and distribution Agreement, comprising of previous fee paid and cash advanced to CURE Accumulated losses Maximum amount insured on bank deposits Payment to Cure for license and distribution agreement Agreement term Minimum product order amount of first 24 months Subsequent yearly minimum product order amount Issue date Maturity date Stated interest rate Principal balance Less debt discount Total Balance, beginning Increase to derivative due to new issuances Derivative (gain) due to conversion Derivative (gain) due to mark to market adjustment Balance, ending Stock price Conversion price Volatility (annual), minimum Volatility (annual), maximum Risk-free rate, minimum Risk-free rate, maximum Years to maturity, minimum Years to maturity, maximum Convertible promissory note Interest rate per annum of note One-time interest payment due at maturity Required issuance of common stock, shares Late penalty charge incurred Conversion rate Fair value of common stock issued Derivative liability at fair value Debt discount Derivative expense charge Debt discount amortized to interest expense New Convertible Promissory Note amount after cancellation of previous Promissory Note New Convertible Promissory Note amount after cancellation of previous Promissory Note, interest per annum Conversion of principal balance into common stock, principal amount Conversion of principal balance into common stock, accrued interest amount Conversion of principal balance into common stock, shares EX-101.PRE 11 atao-20180331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Mar. 31, 2018	Aug. 17, 2018
Document And Entity Information
Entity Registrant Name	ALTAIR INTERNATIONAL CORP.
Entity Central Index Key	0001570937
Document Type	10-K
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float		$ 0
Entity Common Stock, Shares Outstanding		74,509,883
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

XML 13 R2.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Current Assets
Cash	$ 75	$ 7,523
Total current assets	75	7,523
Total assets	75	7,523
Current Liabilities
Accounts payable	17,948	21,590
Loans payable	14,165	14,165
Interest payable	1,354	12,575
Promissory notes due to third parties		241,217
Promissory note due to related party	45,000	51,082
Derivative liability		308,134
Total current liabilities	78,467	648,763
Total Liabilities	78,467	648,763
Stockholders' Equity (Deficit)
Common Stock, $0.001 par value, 75,000,000 shares authorized; 47,747,245 shares issued and outstanding at March 31, 2018 (31,957,000 at March 31, 2017)	47,747	31,957
Additional paid-in capital	432,052	289,940
Common Stock subscribed	267,627	30,000
Accumulated deficit	(825,818)	(993,137)
Total stockholders' equity (deficit)	(78,392)	(641,240)
Total liabilities and stockholders' equity (deficit)	$ 75	$ 7,523

XML 14 R3.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	75,000,000	75,000,000
Common stock, issued	47,747,245	31,957,000	29,947,000
Common stock, outstanding	47,747,245	31,957,000	29,947,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

STATEMENT OF OPERATIONS - USD ($)	12 Months Ended
STATEMENT OF OPERATIONS - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Expenses
Total General and Administrative expenses	$ 3,807	$ 80,253
Write off of Sales and Distrubtion Licenses		560,000
Gain on conversion of debt	(63,417)
Derivative expense	(244,717)	(41,517)
Interest expense	137,008	138,038
Loss (gain) before income taxes	(167,319)	736,774
Income taxes
Net loss (gain)	$ (167,319)	$ 736,774
Loss (gain) per share - Basic	$ .004	$ (0.024)
Weighted Average Shares - Basic	39,441,144	30,902,589

XML 16 R5.htm IDEA: XBRL DOCUMENT

STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)	Common Stock	Additional Paid-In Capital	Capital Stock Subscribed	Accumulated Deficit	Total
Beginning balance, shares at Mar. 31, 2015	29,645,000
Beginning balance, amount at Mar. 31, 2015	$ 29,645	$ 7,146		$ (102,536)	$ (65,745)
Common shares issued for cash, shares	302,000
Common shares issued for cash, amount	$ 302	264,704			265,006
Net income (loss)				(153,827)	(153,827)
Ending balance, shares at Mar. 31, 2016	29,947,000
Ending balance, amount at Mar. 31, 2016	$ 29,947	271,850		(256,363)	45,434
Common shares issued on conversion of Promissory Notes, shares	2,000,000
Common shares issued on conversion of Promissory Notes, amount	$ 2,000	18,000			20,000
Common shares issued for debt, shares	10,000
Common shares issued for debt, amount	$ 10	90			100
Common shares subscribed			30,000		30,000
Net income (loss)				(736,774)	(736,774)
Ending balance, shares at Mar. 31, 2017	31,957,000
Ending balance, amount at Mar. 31, 2017	$ 31,957	289,940	30,000	(993,137)	(641,240)
Common shares issued on conversion of Promissory Notes, shares	15,790,245
Common shares issued on conversion of Promissory Notes, amount	$ 15,790	142,112			157,902
Common shares subscribed			237,627		237,627
Net income (loss)				167,319	167,319
Ending balance, shares at Mar. 31, 2018	47,747,245
Ending balance, amount at Mar. 31, 2018	$ 47,747	$ 432,052	$ 267,627	$ (825,818)	$ (78,392)

XML 17 R6.htm IDEA: XBRL DOCUMENT

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net gain (loss)	$ 167,319	$ (736,774)
Adjustment to reconcile net loss to net cash used in operating activities:
Changes in Accounts payable	(3,642)	21,270
Changes in Interest payable	12,722	12,674
Changes in Fair value of derivative liabilities	(244,717)	(41,517)
Gain on conversion of debt	(63,417)
Changes in Debt discount	124,287	125,364
Write off of Sales and Distrubtion Licenses		560,000
Cash Used In Operating Activities	(7,448)	(58,983)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Promissory Notes issued		43,594
Proceeds from Loans		(12,510)
Proceeds from common stock subscriptions		30,000
Cash provided by financing activities		61,084
NET INCREASE IN CASH AND CASH EQUIVALENTS	(7,448)	2,101
CASH AND CASH EQUIVALENTS
Beginning of year	7,523	5,422
End of year	75	7,523
Supplemental disclosures of cash flow information
Taxes paid
Interest paid
Non-Cash Financing and Investing Activities
Capital Stock subscribed for Conversion of loans from third parties	30,000
Capital Stock subscribed for Conversion of Promissory Notes to third parties	332,213
Capital Stock subscribed for Conversion of Promissory Note to related party	39,373
Capital Stock subscribed for Accrued Interest on Promissory Notes	23,943
Total Capital Stock subscribed	425,529
Promissory Notes issued in settlement of loans		436,586
Debt discount on issuance of Promissory Notes		(249,651)
Promissory Notes issued, net		186,935
Interest expense - debt discount in period	124,287
Derivative Liability on issuance of Promissory Notes		349,651
Reduction of derivative liability in period	252,896	4,227
Reduction of derivative liability - mark to market on conversion of Promissory Notes	55,239
Reduction of derivative liability in period, total	$ 308,135	$ 4,227

XML 18 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND BUSINESS OPERATIONS

12 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

ORGANIZATION AND BUSINESS OPERATIONS

NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS

Organization and Description of Business

On September 23, 2016, the Company and CURE agreed to terminate the Exclusive License and Distribution Agreement for CURE’s Sildenafil Products due to unanticipated costs of obtaining regulatory approvals for the introduction of these pharmaceutical products into the licensed markets. In its place, the Company and CURE agreed to replace it with an Exclusive License and Distribution Agreement for a family of sports related nutraceutical products including a topical active for joint and muscle pain and OTF products for delivery of electrolyte, energy, sleep and recovery actives. The Company was to become the exclusive worldwide distributor for these products. The fee for this new sport products agreement was $560,000, comprised of the $200,000 fee paid for the Sildenafil agreement and the $360,000 advanced as a deposit for future license and distribution agreements. The agreement called for minimum orders of the products by Altair of $1,500,000 in the twenty-four months from the date of signing. As of June 29, 2018, the Company has been unable to generate any sales of the products due to a lack of working capital and the human resources required to introduce the products to market. The Company anticipates that it will not meet the minimum order requirements for the initial 24 month period and accordingly wrote off its $560,000 investment in the agreement in these financial statements for the year ended March 31, 2017.

The Company is currently engaged in identifying and assessing new business opportunities.

Since inception (December 20, 2012) through March 31, 2018, the Company has not generated any revenue and has accumulated losses of $825,818.

XML 19 R8.htm IDEA: XBRL DOCUMENT

GOING CONCERN

12 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

NOTE 2 - GOING CONCERN

XML 20 R9.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.

The Company's bank accounts are deposited in insured institutions. The funds are insured up to $250,000. At March 31, 2018 the Company's bank deposits did not exceed the insured amounts.

Basic and Diluted Income (Loss) Per Share

Income Taxes

Fair Value of Financial Instruments

These tiers include:

Level 1: defined as observable inputs such as quoted prices in active markets;

Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The carrying amounts of financial assets and liabilities, such as cash and accrued liabilities approximate their fair values because of the short maturity of these instruments.

Use of Estimates

Reclassifications

Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the financial statements for the year ended March 31, 2018.

XML 21 R10.htm IDEA: XBRL DOCUMENT

SALES AND DISTRIBUTION LICENSE

12 Months Ended

Mar. 31, 2018

Other Income and Expenses [Abstract]

SALES AND DISTRIBUTION LICENSE

NOTE 4 – SALES AND DISTRIBUTION LICENSE

On September 23, 2016, the Company and CURE agreed to terminate the Exclusive License and Distribution Agreement for CURE’s Sildenafil Products due to unanticipated costs of obtaining regulatory approvals for the introduction of these pharmaceutical products into the Asian markets and to replace it with an Exclusive License and Distribution Agreement for a family of sports related nutraceutical products including a topical active for joint and muscle pain and OTF products for delivery of electrolyte, energy, sleep and recovery actives, The Company became the exclusive worldwide distributor for these products. The fee for this new Exclusive License and Distribution Agreement was $560,000, comprised of the $200,000 fee paid for the Sildenafil agreement and the $360,000 advanced as a deposit for future license and distribution agreements. This Agreement has a ten year term and requires minimum product orders of $1,500,000 in the first 24 months from the effective date of the Agreement and $1,500,000 for each year thereafter. As of June 29, 2018, the Company had been unable to generate any sales of the products due to a lack of working capital and the human resources required to introduce the products to market. The Company anticipates that it will not meet the minimum order requirements for the initial 24 month period and accordingly wrote off its $560,000 investment in the agreement as at March 31, 2017 in these financial statements.

XML 22 R11.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTES

12 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

PROMISSORY NOTES

NOTE 5 – PROMISSORY NOTES

A summary of outstanding convertible notes as of March 31, 2018, is as follows:

Note Holder

Issue Date

Maturity Date

Stated Interest Rate

Principal Balance 03/31/2018

Enpos Sports, LLC

9/23/2016

9/23/2017

—

Williams Ten, LLC

9/29/2016

9/29/2017

—

Strips Nutrition, Inc.

9/29/2016

9/29/2017

—

Mr. Fred Lee

9/29/2016

9/29/2017

—

Mr. Brent McMahon

9/29/2016

9/29/2017

—

Evolution Equities Corporation

9/29/2016

9/29/2017

—

Enpos Sports, LLC

10/14/2016

10/14/2017

—

Total

—

Less debt discount

—

Total

—

A summary of the activity of the derivative liability for the notes above is as follows:

Balance at March 31, 2016	$	100,000
Increase to derivative due to new issuances		249,651
Derivative (gain) due to mark to market adjustment		(41,517	)
Balance at March 31, 2017		308,134
Derivative (gain) due to conversion		(63,417	)
Derivative (gain) due to mark to market adjustment		(244,717	)
Balance at March 31, 2018	$	—

Inputs	September 30, 2017		Initial Valuation
Stock price	$	.01	$	.01
Conversion price	$	.01	$	.01
Volatility (annual)		74.2%		248.1% - 248.6%
Risk-free rate		1.06%		.59% - .60%
Years to maturity		.25		1

The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.

XML 23 R12.htm IDEA: XBRL DOCUMENT

LOANS PAYABLE

12 Months Ended

Mar. 31, 2018

Payables and Accruals [Abstract]

LOANS PAYABLE

NOTE 6 – LOANS PAYABLE

XML 24 R13.htm IDEA: XBRL DOCUMENT

SHARE SUBSCRIPTIONS

12 Months Ended

Mar. 31, 2018

Notes to Financial Statements

SHARE SUBSCRIPTIONS

NOTE 7 – SHARE SUBSCRIPTIONS

On December 30, 2016, the Company received $30,000 from a third party as a subscription for 3,000,000 common shares at $0.01 per share. These shares were issued to the subscribers on April 19, 2018.

XML 25 R14.htm IDEA: XBRL DOCUMENT

COMMON STOCK

12 Months Ended

Mar. 31, 2018

Stockholders' Equity Note [Abstract]

COMMON STOCK

NOTE 8 – COMMON STOCK

The Company has 75,000,000 common shares authorized with a par value of $0.001 per share.

The Company had 29,947,000 common shares issued and outstanding at March 31, 2016.

XML 26 R15.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

12 Months Ended

Mar. 31, 2018

RELATED PARTY TRANSACTIONS

NOTE 9 – RELATED PARTY TRANSACTIONS

XML 27 R16.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

12 Months Ended

Mar. 31, 2018

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 10 – SUBSEQUENT EVENTS

On December 30, 2016, the Company received $30,000 from a third party as a subscription for 3,000,000 common shares at $0.01 per share. These shares were issued to the subscribers on April 19, 2018.

XML 28 R17.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the years ending March 31, 2018 and 2017.
Cash and Cash Equivalents	Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company's bank accounts are deposited in insured institutions. The funds are insured up to $250,000. At March 31, 2018 the Company's bank deposits did not exceed the insured amounts.
Basic and Diluted Income (Loss) Per Share	Basic and Diluted Income (Loss) Per Share The Company computes loss per share in accordance with “ASC-260”, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive.
Income Taxes	Income Taxes The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
Fair Value of Financial Instruments	Fair Value of Financial Instruments FASB ASC 820 "Fair Value Measurements and Disclosures" establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. These tiers include: Level 1: defined as observable inputs such as quoted prices in active markets; Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The carrying amounts of financial assets and liabilities, such as cash and accrued liabilities approximate their fair values because of the short maturity of these instruments.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Reclassifications	Reclassifications Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the financial statements for the year ended March 31, 2018.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTES (Tables)

12 Months Ended

Mar. 31, 2018

Promissory Notes

Summary of outstanding convertible notes

Note Holder

Issue Date

Maturity Date

Stated Interest Rate

Principal Balance 03/31/2018

Enpos Sports, LLC

9/23/2016

9/23/2017

—

Williams Ten, LLC

9/29/2016

9/29/2017

—

Strips Nutrition, Inc.

9/29/2016

9/29/2017

—

Mr. Fred Lee

9/29/2016

9/29/2017

—

Mr. Brent McMahon

9/29/2016

9/29/2017

—

Evolution Equities Corporation

9/29/2016

9/29/2017

—

Enpos Sports, LLC

10/14/2016

10/14/2017

—

Total

—

Less debt discount

—

Total

—

Summary of activity of derivative liability for convertible notes

Balance at March 31, 2016	$	100,000
Increase to derivative due to new issuances		249,651
Derivative (gain) due to mark to market adjustment		(41,517	)
Balance at March 31, 2017		308,134
Derivative (gain) due to conversion		(63,417	)
Derivative (gain) due to mark to market adjustment		(244,717	)
Balance at March 31, 2018	$	—

Summary of quantitative information about significant unobservable inputs

Inputs	September 30, 2017		Initial Valuation
Stock price	$	.01	$	.01
Conversion price	$	.01	$	.01
Volatility (annual)		74.2%		248.1% - 248.6%
Risk-free rate		1.06%		.59% - .60%
Years to maturity		.25		1

XML 30 R19.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND BUSINESS OPERATIONS (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2015
Organization And Business Operations
Cost of acquiring Exclusive License and Distribution Agreement				$ 200,000
Cash advanced to CURE				360,000
Fee paid for new Exclusive License and distribution Agreement, comprising of previous fee paid and cash advanced to CURE	$ 560,000			$ 360,000
Write off of Sales and Distrubtion Licenses			$ 560,000
Accumulated losses		$ (825,818)	$ (993,137)

XML 31 R20.htm IDEA: XBRL DOCUMENT

GOING CONCERN (Details Narrative) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (825,818)	$ (993,137)

XML 32 R21.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	Mar. 31, 2018 USD ($)
Accounting Policies [Abstract]
Maximum amount insured on bank deposits	$ 250,000

XML 33 R22.htm IDEA: XBRL DOCUMENT

SALES AND DISTRIBUTION LICENSE (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2015
Other Income and Expenses [Abstract]
Payment to Cure for license and distribution agreement				$ 200,000
Fee paid for new Exclusive License and distribution Agreement, comprising of previous fee paid and cash advanced to CURE	$ 560,000			$ 360,000
Agreement term	10 years
Minimum product order amount of first 24 months	$ 1,500,000
Subsequent yearly minimum product order amount	$ 1,500,000
Write off of Sales and Distrubtion Licenses			$ 560,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTES - Summary of outstanding convertible notes (Details)	12 Months Ended
	Mar. 31, 2018 USD ($)
Enpos Sports, LLC (1)
Issue date	Sep. 23, 2016
Maturity date	Sep. 23, 2017
Stated interest rate	6.00%
Principal balance
Williams Ten, LLC new note
Issue date	Sep. 29, 2016
Maturity date	Sep. 29, 2017
Stated interest rate	6.00%
Principal balance
Strips Nutrition, Inc.
Issue date	Sep. 29, 2016
Maturity date	Sep. 29, 2017
Stated interest rate	6.00%
Principal balance
Mr. Fred Lee
Issue date	Sep. 29, 2016
Maturity date	Sep. 29, 2017
Stated interest rate	6.00%
Principal balance
Mr. Brent McMahon
Issue date	Sep. 29, 2016
Maturity date	Sep. 29, 2017
Stated interest rate	6.00%
Principal balance
Evolution Equities Corporation
Issue date	Sep. 29, 2016
Maturity date	Sep. 29, 2017
Stated interest rate	6.00%
Principal balance
Enpos Sports, LLC (2)
Issue date	Oct. 14, 2016
Maturity date	Oct. 14, 2017
Stated interest rate	6.00%
Principal balance
Totals
Principal balance
Less debt discount
Total

XML 35 R24.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTES - Summary of activity of derivative liability for convertible notes (Details) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Debt Disclosure [Abstract]
Balance, beginning	$ 308,134	$ 100,000
Increase to derivative due to new issuances		249,651
Derivative (gain) due to conversion	(63,417)
Derivative (gain) due to mark to market adjustment	(244,717)	(41,517)
Balance, ending		$ 308,134

XML 36 R25.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTES - Summary of quantitative information about significant unobservable inputs (Details)	12 Months Ended
	Mar. 31, 2018 $ / shares
Stock price	$ 0.01
Conversion price	$ .01
Volatility (annual), maximum	74.20%
Risk-free rate, maximum	1.06%
Years to maturity, maximum	3 months
Initial Valuation
Stock price	$ .01
Conversion price	$ .01
Volatility (annual), minimum	248.10%
Volatility (annual), maximum	248.60%
Risk-free rate, minimum	0.59%
Risk-free rate, maximum	0.60%
Years to maturity, maximum	1 year

XML 37 R26.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTES (Details Narrative) - USD ($)	12 Months Ended
PROMISSORY NOTES (Details Narrative) - USD ($)	Mar. 31, 2018	Mar. 31, 2017	Oct. 14, 2016	Sep. 29, 2016	Sep. 23, 2016	Mar. 31, 2016	Mar. 06, 2015
Derivative liability at fair value		$ 308,134				$ 100,000
Williams Ten, LLC original note
Convertible promissory note							$ 100,000
One-time interest payment due at maturity	$ 10,000
Required issuance of common stock, shares	10,000
Late penalty charge incurred	$ 11,000
Conversion rate	50.00%
Fair value of common stock issued							9,091
Derivative liability at fair value							100,004
Debt discount							$ 90,909
Derivative expense charge	$ 9,095
Williams Ten, LLC new note
New Convertible Promissory Note amount after cancellation of previous Promissory Note				$ 121,000
New Convertible Promissory Note amount after cancellation of previous Promissory Note, interest per annum				6.00%
Conversion of principal balance into common stock, principal amount	111,000	$ 10,000
Conversion of principal balance into common stock, accrued interest amount	$ 6,691
Conversion of principal balance into common stock, shares	11,769,123	1,000,000
Amount on note outstanding
Gain on conversion of note	15,215
Gain on change in fair value of derivative	16,504
Strips Nutrition, Inc.
Convertible promissory note				$ 13,850
Interest rate per annum of note				6.00%
Derivative liability at fair value				$ 10,960
Debt discount				10,960
Debt discount amortized to interest expense	2,733
Conversion of principal balance into common stock, principal amount	13,850
Conversion of principal balance into common stock, accrued interest amount	$ 831
Conversion of principal balance into common stock, shares	1,468,100
Amount on note outstanding
Gain on conversion of note	1,886
Gain on change in fair value of derivative	2,056
Mr. Fred Lee
Convertible promissory note				$ 13,769
Interest rate per annum of note				6.00%
Derivative liability at fair value				$ 10,896
Debt discount				10,896
Debt discount amortized to interest expense	2,716
Conversion of principal balance into common stock, principal amount	13,769
Conversion of principal balance into common stock, accrued interest amount	$ 826
Conversion of principal balance into common stock, shares	1,459,502
Amount on note outstanding
Gain on conversion of note	1,877
Gain on change in fair value of derivative	2,047
Mr. Brent McMahon
Convertible promissory note				$ 160,000
Interest rate per annum of note				6.00%
Derivative liability at fair value				$ 126,612
Debt discount				126,612
Debt discount amortized to interest expense	31,567
Conversion of principal balance into common stock, principal amount	150,000	$ 10,000
Conversion of principal balance into common stock, accrued interest amount	$ 7,902
Conversion of principal balance into common stock, shares	15,790,245	1,000,000
Amount on note outstanding
Gain on conversion of note	20,453
Gain on change in fair value of derivative	22,303
Evolution Equities Corporation
Convertible promissory note				$ 84,373
Interest rate per annum of note				6.00%
Derivative liability at fair value				$ 66,766
Debt discount				$ 66,766
Debt discount amortized to interest expense	16,645
New Convertible Promissory Note amount after cancellation of previous Promissory Note	$ 45,000
New Convertible Promissory Note amount after cancellation of previous Promissory Note, interest per annum	6.00%
Conversion of principal balance into common stock, principal amount	$ 39,373
Conversion of principal balance into common stock, accrued interest amount	$ 5,062
Conversion of principal balance into common stock, shares	4,443,565
Amount on note outstanding
Gain on conversion of note	17,898
Gain on change in fair value of derivative	5,854
Enpos Sports, LLC (1)
Convertible promissory note					$ 35,000
Interest rate per annum of note					6.00%
Derivative liability at fair value					$ 27,673
Debt discount					$ 27,673
Debt discount amortized to interest expense	6,445
Conversion of principal balance into common stock, principal amount	35,000
Conversion of principal balance into common stock, accrued interest amount	$ 2,135
Conversion of principal balance into common stock, shares	3,713,452
Amount on note outstanding
Gain on conversion of note	4,766
Gain on change in fair value of derivative	5,197
Enpos Sports, LLC (2)
Convertible promissory note			$ 8,594
Interest rate per annum of note			6.00%
Derivative liability at fair value			$ 6,744
Debt discount			$ 6,744
Debt discount amortized to interest expense	1,940
Conversion of principal balance into common stock, principal amount	8,594
Conversion of principal balance into common stock, accrued interest amount	$ 494
Conversion of principal balance into common stock, shares	908,896
Amount on note outstanding
Gain on conversion of note	1,322
Gain on change in fair value of derivative	$ 1,278

XML 38 R27.htm IDEA: XBRL DOCUMENT

LOANS PAYABLE (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended	12 Months Ended
LOANS PAYABLE (Details Narrative) - USD ($)	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2016	Mar. 31, 2016	Jul. 22, 2015
Payables and Accruals [Abstract]
Loan from third party					$ 25,000
Additional loan from third party			$ 9,990	$ 4,175
Loans obtained from third party	$ 2,500	$ 11,350

XML 39 R28.htm IDEA: XBRL DOCUMENT

SHARE SUBSCRIPTIONS (Details Narrative)	Mar. 31, 2018 shares
Notes to Financial Statements
Common Stock subscribed, shares to be issued	3,000,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

COMMON STOCK (Details Narrative) - USD ($)	12 Months Ended
COMMON STOCK (Details Narrative) - USD ($)	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Common stock, authorized	75,000,000	75,000,000
Common stock, par value	$ 0.001	$ 0.001
Cash proceeds from sale of common stock			$ 265,006
Common stock, shares issued as result of split	47,747,245	31,957,000	29,947,000
Common stock, shares outstanding as result of split	47,747,245	31,957,000	29,947,000
Common stock issued on conversion of convertible Promissory Notes, shares	15,790,245	2,000,000
Common stock issued on conversion of convertible Promissory Notes, amount	$ 157,902	$ 20,000
Shares issued as required under terms of original Promissory Note with Williams Ten LLC		10,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended	45 Months Ended
	Sep. 30, 2016	Mar. 30, 2017	Sep. 29, 2016	Mar. 31, 2018
Related Party Transactions [Abstract]
Loans from Directors			$ 84,374
One time payment to officer upon signing of consulting agreement			$ 10,000
Monthly payment to officer per consulting agreement		$ 5,000
Additional payment for services provided	$ 5,000
Amounts paid pursuant to contract				$ 33,350
Amounts payable purusant to contract				$ 14,150

XML 42 R31.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		4 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Apr. 19, 2018	Aug. 06, 2018
Subsequent Events [Abstract]
Common stock subscriptions, shares issued	3,000,000
Promissory note conversions, shares issued	23,762,638
Advances to the Company pursuant to Memorandum of Understanding		$ 75,770

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end